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ABSTRACT 
 
Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. 
Knowledge of the predominant agents associated with CAP locally is essential, as it represents the 
basis for empiric antibiotic treatment. The objective of this study was to establish polymerase 
chain reaction (PCR)-based methods that could be used to identify CAP pathogens. Real-time 
PCR assays were developed to detect 10 viral and 5 non-viral pathogens as well as 2 internal 
controls using SYBR Green I and TaqMan probes, in singleplex and multiplex reactions. Six 
multiplex assays, with sensitivities of 1-10 copies/µl, were successfully developed to 
simultaneously detect 12 organisms. These reactions were used to test a limited number of patient 
and simulated samples. Data from the real-time PCR methods compared favourably to those from 
commercially available conventional PCR kits. These detection methods could be used to 
complement each other in prevalence studies and in selected diagnostic applications. 
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CHAPTER 1: INTRODUCTION 
 
 
 
1.1. Community-acquired pneumonia  
 
Pneumonia is an inflammatory response of the host to uncontrolled multiplication of 
pathogenic organisms in the distal airways and alveoli (Woodhead, 2002). It is an infection 
resulting from microbial invasion of the normally sterile lower respiratory tract and lung 
tissue. It may be caused by bacteria, viruses or parasites and is clinically characterised by 
pulmonary or extrapulmonary signs and symptoms. On chest radiography, the inflammation 
within and around the alveolar spaces of the lung can be visualized as an infiltrate, which 
distinguishes pneumonia from other lower respiratory tract diseases. However, it is not 
possible to distinguish between different types of pneumonia on clinical or biochemical 
parameters alone and the diagnosis has to be microbiological. 
 
Community-acquired pneumonia (CAP), which is pneumonia not acquired from a hospital or a 
long-term care facility (Lutfiyya et al., 2006), is a major cause of morbidity and mortality 
worldwide. Symptoms commonly found in patients with CAP include coughing, sputum 
production, breathlessness, chest pain and haemoptysis (coughing up blood) amongst others 
(Woodhead, 2002). Two types of CAP are commonly recognised - typical and atypical. 
Typical pneumonia is usually caused by bacteria such as Streptococcus pneumoniae, 
Haemophilus influenza and Moraxella catharralis, whilst atypical pneumonia can be caused 
by respiratory viruses, Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella 
pneumophila. 
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CAP remains a serious illness that can have a significant impact on patients as well as society. 
Risk factors for CAP are: age over 60 years, alcoholism, immunosuppression, asthma and 
institutionalization. The microbial patterns in CAP differ considerably across studies, 
depending on the geographic area studied, the patient population included, and the nature and 
extent of the diagnostic techniques used (Garcia-Sastre et al., 1998). Knowledge of the major 
microbial patterns in CAP is essential, as it represents the basis for initial decisions about its 
antimicrobial treatment. Empiric antimicrobial treatment must be initiated based on clinical 
symptoms, radiographic and laboratory findings, and specific epidemiologic risk factors. As 
early intervention with appropriate antibiotics has been shown to improve mortality and may 
decrease transmission of infection, more rapid and sensitive tests would greatly improve the 
care of patients with pneumonia (Leroy et al., 1995) by identifying causative organisms and 
providing knowledge of their regional and geographic distribution. 
 
Changes have occurred in the demographics of the patient population vulnerable to CAP in 
South Africa, with increasing numbers of individuals over the age of 65 and HIV positive 
persons bearing the burden of the disease. This shift has increased not only the total number of 
individuals at risk of pneumonia, but also the variety of pathogens found in association with 
the infections (Templeton et al., 2005). The patient’s age may be a major discriminating factor 
between typical and atypical pneumonia. Young adults are more prone to atypical causes, and 
very young and older persons are more predisposed to typical causes. This is however not the 
case with patients with HIV/ AIDS and other immunocompromised conditions (Lutfiyya et al., 
2006). 
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1.2. Diagnosis of CAP 
Early diagnosis of pneumonia is important and timeous initiation of appropriate antimicrobial 
treatment is associated with a better outcome of patients with CAP, while delayed therapy is 
associated with an increased risk of death (Metlay and Fine, 2003). The microbiological 
diagnosis of CAP is usually made by microscopy and culture of sputum and blood, or by 
serological examinations which include detection of urine antigens for pneumococcus and 
Legionella spp., and antibodies for M. pneumoniae. The diagnostic value of positive blood 
culture is high; however its sensitivity can be low. Diagnosis of viral respiratory tract 
infections using viral culture, antigen detection or serology is either too slow or too insensitive 
to be applicable in clinical practice (Gunson et al., 2005). It should also be noted that sputum 
samples from pneumonia patients are routinely used for bacteriological tests whilst 
nasopharyngeal aspirates and swabs are standard specimens for respiratory viral and atypical 
(mycoplasmal and chlamydial) diagnosis (Kok and Higgins, 1997). 
 
Restriction fragment length polymorphism (RFLP) was one of the first molecular methods 
applied to the identification of pneumonia (Singh et al., 2006) whereby restriction enzymes  
were used to digest DNA to generate different size fragments and fragments were then 
analyzed by gel electrophoresis. However RFLP requires growth of the organism in culture 
and is more useful in the examination of disease transmission and strain identification rather 
than clinical identification (Chan and Morris, 2007). Most currently used molecular techniques 
are based on polymerase chain reaction (PCR) technology (Yang and Rothman, 2004). PCR 
methods are more reliable, specific and sensitive, however, they have not yet been accepted as 
the first choice for routine diagnosis due to the high cost particularly when several agents are 
targeted (Brittain-Long et al., 2008). Nevertheless, methods such as real-time PCR, which 
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combines nucleic acid amplification with amplicon detection, have revolutionized the way 
clinical microbiological laboratories identify human pathogens.  
 
1.3.  PCR 
PCR is a revolutionary method developed by Kary Mullis in the 1980s (Mullis, 1990) and 
PCR-based approaches have allowed molecular biology to advance greatly by allowing 
researchers to manipulate DNA effortlessly, thereby facilitating procedures such as cloning 
and enabling endeavors such as the Human Genome Project. PCR is typically performed on a 
DNA template, which is either single or double-stranded. The basic steps of PCR in a clinical 
microbiology setting include extraction of DNA or RNA from either a cultured pathogen or 
from a patient sample. In the case of RNA, reverse transcription must be carried out to 
transform the RNA to complementary DNA (cDNA). For most applications, at least a partial 
DNA sequence of the organism must be known to design primers that flank that region and 
can thus hybridize to the target DNA sequence. A heat-stable DNA polymerase, most 
commonly derived from the thermophilic bacterium Thermus aquaticus and called Taq, is also 
required, along with magnesium ions in the buffer and deoxynucleotide triphosphates 
(dNTPs). The reaction is performed by temperature cycling in a thermocycler and can be 
summarized in three steps: (i) A High temperature of >90oC is applied to denature (melt) the 
strands of the double stranded DNA. The required melting temperature and period of melting 
depends on the length and occasionally the sequence of the template as well as the instrument 
used, (ii) The temperature is then lowered (50-75oC) to allow primers to anneal to the 
template, and (iii) finally the temperature is set at approximately 72oC, which is optimum for 
the Taq polymerase to extend the primers by incorporating dNTPs thereby creating a DNA 
complementary strand (Figure 1.1) (Mackay et al., 2002). A typical PCR reaction lasts about 
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30 to 50 cycles and the amount of DNA theoretically doubles with each cycle in the 
exponential phase provided there is a sufficient amount of nucleotides and primers. Gel 
electrophoresis, typically using ethidium bromide to visualize the amplification products, is 
frequently used to estimate the size of the amplicon and this is both cheap and simple to 
implement.  
 
1.4. Real-time PCR 
Real-time PCR refers to amplification of DNA (by PCR) that is monitored while the 
amplification is taking place (Valasek and Repa, 2005). It symbolizes yet another 
technological leap forward that has unlocked new and powerful applications for researchers 
worldwide. PCR has advanced from detection of products at the end point of the reaction in 
conventional PCR to real-time PCR where detection is done while the reaction is occurring 
(Parashar et al., 2006). 
 
In real-time PCR, fluorescent reporter molecules are used to monitor the production of 
amplification products at each cycle of the PCR reaction obviating the need for gel 
electrophoresis to detect amplification products (Bustin, 2005). The detection of products is 
made possible by including fluorescent molecules in the reaction that report increases in the 
amount of DNA by a proportional increase in the fluorescent signal.  
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Figure 1.1: The PCR temperature cycle. Step 1: Temperature is raised to 90oC or more to denature the double-
stranded DNA strands; Step 2: Temperature is lowered significantly to allow the primers to anneal to the 
template; Step 3: temperature is set at 72oC to allow the Taq polymerase enzyme to extend the primers. DNA 
theoretically doubles after each cycle provided the nucleotides and primers are not limiting. Adapted from 
Mulhardt and Beese (2006). 
 
Real-time PCR can be divided into four major phases (Figure 1.2) and these are: the linear 
ground phase, early exponential phase, log-linear (known also as exponential) phase, and 
plateau phase (Tichopad et al., 2003). For the duration of the linear ground phase which is 
typically the first 10–15 cycles, PCR is just beginning, and fluorescence emission at each 
cycle has not yet exceeded the background. Baseline fluorescence is calculated at this stage. 
During the early exponential phase, the amount of fluorescence has reached a threshold where 
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it is considerably higher than background levels. The cycle at which this occurs is known as Ct 
(threshold) (Heid et al., 1996). During the log-linear phase, PCR attains its most favourable 
amplification period with the PCR product doubling after every cycle in ideal reaction 
circumstances thus allowing researchers to amplify specific pieces of DNA more than a 
billion-fold (Figure 1.1) (Mullis, 1990). Lastly, the plateau stage is reached when reaction 
components become limiting and the fluorescence intensity is no longer useful for data 
calculation (Bustin, 2000). 
 
Real-time PCR is considerably faster than conventional PCR with standard detection methods, 
hence for some time this technology was referred to as rapid-cycle real-time PCR (Espy et al., 
2006). Also, the sensitivity of assays is often improved and the hands-on time is significantly 
reduced (van de Pol et al., 2006). Since the nucleic acid amplification and detection steps are 
performed in the same closed vessel, the risk for release of amplified product into the 
environment, and resultant contamination of subsequent analyses, is minimal compared with 
agarose based end-point PCR methods. Overall, the combination of excellent sensitivity and 
specificity, low contamination risk, ease of performance and speed has made real-time PCR an 
appealing alternative to other methods for diagnosing infectious diseases (Morozumi et al., 
2006). 
 
There are various chemistries available to obtain a fluorescent signal from the synthesis of 
product in real-time PCR. These are basically grouped into two groups namely non-specific 
and specific detection chemistries. 
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Figure 1.2: PCR amplification curve indicating the different phases of PCR amplification. The PCR amplification 
curve charts the accumulation of fluorescence signal at each reaction cycle. The curve can be divided into four 
different phases: the linear ground, early exponential, log-linear, and plateau phases. Data collected from these 
phases are vital for calculating background signal, cycle threshold (Ct), and amplification efficiency. Adapted 
from Wong and Medrano (2005). 
 
1.4.1. Non-specific detection chemistries 
Nonspecific detection uses intercalating dyes such as SYBR Green I, which binds non-
specifically to double stranded DNA and has an excitation and emission maxima of 494 nm 
and 521nm, respectively (Soheili and Samiei, 2005). SYBR Green I displays little 
fluorescence when free in solution, but this fluorescence increases up to 1000-fold when the 
dye is bound to double-stranded DNA thus overall fluorescence is proportional to the amount 
of double-stranded DNA present (Valasek and Repa, 2005) (Figure 1.3). Melting-curve 
analysis is thereafter used to identify different products, including non-specific ones. This 
curve is generated by increasing the temperature in small increments. The highest level of 
fluorescence is observed when the DNA is double-stranded and as the double-stranded DNA 
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denatures, the fluorescence decreases. A signature peak is observed at the amplicon melting 
temperature (Tm, the temperature at which 50% of the base pairs of a double stranded DNA 
molecule are separated) and this differentiates it from other products which melt at different 
temperatures (Figure 1.4) such as primer-dimers (Valasek and Repa, 2005). However, it 
should be noted that Tm values may vary as the reagent concentrations (DMSO, magnesium 
chloride, template DNA and SYBR Green I) change. Also, the rate of temperature transition 
during the melting analysis has an effect on the Tm value generated (Giglio et al., 2003). The 
area under the peak is proportional to the amount of product produced ((Wilhelm and Pingoud, 
2003). Therefore, melting curve analysis may be used for quantification. Primer-dimers are 
typically shorter than the target product and as a result, they have a melting temperature lower 
than that of the product and can be easily distinguished using a melting curve. The melting 
temperature is a property of the amplicon that is dependent on the concentration of double-
stranded DNA, its length and nucleotide composition (Mackay et al., 2002). 
 
Advantages displayed by assays using DNA-binding dyes are: (1) their ability to be integrated 
without much difficulty into optimized and long-established protocols, and (2) their 
affordability, as there is no probe-related cost. As a result, they are very useful for optimizing 
a PCR reaction; for instance, when testing any interaction between the primers by melt curve 
analysis, and running initial, investigative screens of multiple amplicons before using a probe-
based protocol, as was done in this study.  
 
Despite their advantages, DNA-binding dye assays have disadvantages that include (1) their 
indiscriminate binding to any double-stranded DNA, which may result in fluorescence coming 
up in the “no template controls” (NTC) owing to dye molecules binding to primer dimers, (2) 
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the mandatory use of melting curves since these assays are no more specific than conventional 
PCR making data analysis more complex (Bustin and Nolan, 2004), and (3) difficulty in 
establishing multiplex reactions due to preferential binding of DNA-binding dyes, particularly 
SYBR Green I, to selected amplicons. 
 
Figure 1.3: Real-time PCR SYBR Green I Technology. Taken from Bio-Rad (2007). 
 
  
 
Figure 1.4: Melting curve analysis. Melting temperature helps distinguish specific and non-specific product. 
Taken from Wittwer et al (1998). 
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1.4.2. Specific detection chemistries 
Specific detection chemistries include dual labeled probes (exemplified by TaqManTM probes, 
also known as 5’ nuclease probes), minor groove binding (MGB) probes, molecular beacons, 
and more newly developed fluorescent labeled primers: LuxTM, SunriseTM and ScorpionTM 
primers (Gunson et al., 2006). Originally, 5’ nuclease-based formats used a 5’-32P-labelled 
probe and the release of the 32P-label was used to measure probe hydrolysis (Holland et al., 
1991). Subsequently, dual labeled probes were used. Essentially, the TaqMan probe is a short, 
sequence-specific oligonucleotide that contains a 5’ fluorescent dye and a 3’quenching dye.  
When the fluorescent and reporter are in close proximity, that is to say, they are both attached 
to the same short oligonucleotide, the quencher absorbs the signal from the reporter and at this 
stage, no signal is observed. To produce a light signal, the TaqMan probe binds to a 
complementary strand of DNA at 72oC. At this temperature, Taq polymerase is active and 
cleaves the 5’ end of the TaqMan probe (5’ nuclease activity), separating the fluorescent dye 
from the quenching dye (Figure 1.5) (Espy et al., 2006). The cleaved fluorescent dye 
accumulates after each temperature cycle and can be measured at any time during the PCR 
cycling. 
 
The major advantage of using specific chemistries is that specificity no longer resides with the 
primers; instead, the probe introduces an added level of specificity and as a result, nonspecific 
amplification due to mispriming or primer–dimer artifacts is not noted by the fluorescence 
detector and no signal is produced. This eliminates the need for melting curves, or sequence 
analysis to verify the identity of the amplicon (Bustin and Nolan, 2004). In addition, the fact 
that probes can be labeled with different, distinguishable reporter dyes allows for the detection 
of amplification products from several distinct sequences in a single PCR multiplex reaction 
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(Bustin and Nolan, 2004). However, the main disadvantage with specific chemistries is that 
because of its specificity, inhibitors that impede amplification efficiency go unnoticed. 
Consequently, dyes such as SYBR Green I should be used to optimize primers and reaction 
conditions prior to any experiments to make certain that amplification inhibitors are absent. 
Also, because primer-dimers cannot be detected by probes, it is important to check for their 
presence by gel electrophoresis especially when high Ct values are obtained. Another 
disadvantage is that the cost associated with these chemistries is high because each target 
requires its own specific probe. This becomes particularly expensive when amplifying 
multiple targets, as costs escalate very rapidly (Bustin and Nolan, 2004). 
 
Figure 1.5: Real-time PCR 5’ nuclease probe technology. Taken from Lie and Petropoulos (1998). 
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1.5. Real-time PCR platform 
As the use of real-time PCR becomes popular, a range of real-time PCR instruments are 
becoming available, ranging from the iCycler (Bio-Rad), the SmartCycler (Cepheid) and the 
Sentinel (Stratagene) amongst others. The real-time PCR instrument used in this study is the 
Chromo4 (Bio-Rad). 
 
 
Figure 1.6: Fluorescence spectra of the Chromo4 real-time detection system. The standard photonics shuttle has 4 
colour channels. The fluorescent dyes detected in each channel as well as the detection wavelengths are indicated 
above the spectra. The emission wavelength of each of the fluorescent dyes is indicated on the x-axis. Adapted 
from Bio-Rad (2008). (FAM: 6-carboxyfluorescein; TET: 6-carboxy-4,7,2’,7’-tetrachloro-fluorescein; VIC; 
ROX: 6-carboxy-X-rhodamine N-succinimidyl ester; HEX: hexachloro-6-carboxyfluoroscein; Cy3: 
indocarbocyanine; TAMRA: (6-carboxy-tetramethyl-rhodamine); Cy5: tetramethyl-indodicarbocyanine; JOE:  
2′,7′-dimethoxy-4′5′-dichloro-6-carboxyfluoresce in). 
 
The photonics shuttle is the heart of the Chromo4 detector. It is a compact unit that contains 
all the components for real-time excitation and detection. This shuttle has four channels 
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meaning it can detect up to four colours in the same reaction vessel. These channels are shown 
in figure 1.6 along with the respective fluorescent dyes that have detection wavelengths that 
fall within the range of these channels.  
 
General fundamentals of fluorescent dyes are that they should sufficiently excite and emit 
energy at different wavelengths without any overlap, they must bind easily to DNA molecules, 
must be detectable at low concentrations and must be still functional after long term storage 
(Mackay, 2007). There are a number of quenchers available. Examples of the most common 
are black hole quencher 1, 2 and 3 (BHQ1, 2 and 3), BlackBerry quencher (BBQ) and minor 
groove binding (MGB) quencher. 
 
1.6. Multiplex real-time PCR 
 
Multiplex real-time PCR is a modification of real-time PCR in which two or more target 
sequences can be amplified by including more than one pair of primers and probes in a single 
reaction vessel, saving time and effort in the laboratory (Markoulatos et al., 2002). This allows 
for colour multiplexing where probes labeled with different fluorescent dyes are present. Dyes 
like SYBR Green I cannot be used in multiplex reactions because they are not sequence 
specific (Wittwer et al., 2001), they have been shown to inhibit PCR (Gudnason et al., 2007), 
bind preferentially to GC-rich sequences (Giglio et al., 2003) and have an effect on melting 
curve analysis in that the melting temperature has been shown to be highly dependent on the 
dye (Ririe et al., 1997) and DNA concentration (Xu et al., 2000). It is important to carefully 
select the fluorescence dyes one will use when multiplexing and to make sure that they are 
spectrally well separated and there is no bleed-through into other dye layers which will result 
in false positives (Figure 1.6). 
Chapter 1: Introduction 
 15 
The utilization of multiplex assays reduces overall testing costs in that a lower sample volume 
is required. This is particularly an advantage in a clinical setting when the volume of a sample 
received is low. In addition to this, less reagents and consumables are required and turn around 
times are reduced permitting a high throughput (Cirino et al., 2007). The development of 
multiplex real-time PCR has been a complicated process because of the limited number of 
existing fluorophores as well as the great deal of trial and error required. While excitation by a 
single wavelength results in bright emissions from a suitably receptive fluorophore being 
produced, the number of fluorophores that can be excited by that wavelength is limited 
(Mackay, 2004). In order to optimize the multiplex assay, each separate PCR reaction must be 
optimized separately before being assessed when added together. 
 
A problem inherent in multiplex reactions is that PCR efficiencies may decrease with the 
inclusion of multiple primer sets and probes due to preferential amplification of certain 
specific targets (Markoulatos et al., 2002). Differences in starting target template 
concentrations can also cause one reaction to out-compete the other resulting in false negative 
results (Exner and Lewinski, 2002) and this is why careful planning of the multiplex reaction 
is essential to minimize the chances of primer-dimer formation and reduced reaction 
efficiency.  
 
1.7. Dual Priming Oligonucleotide (DPO) system 
Proper priming between an oligonucleotide primer and its DNA template is essential for a 
successful PCR reaction. However, even with rigid primer design and optimization of PCR 
reaction conditions, a high level of non-specific priming and amplification of non-specific 
product is still present. The DPO technology is a novel principle developed to counteract the 
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effects of mismatched priming that cannot be avoided in the currently used PCR system (Chun 
et al., 2007). Two separate priming regions joined by a polydeoxyinosine linker, which is not 
involved in priming, constitute the DPO (Figure 1.7). The linker joining the 2 priming regions 
has a low melting temperature thus changes into a bubble-like shape at high temperatures. Its 
function is to physically separate the long DPO primer (34-42 nucleotides) into two priming 
sites resulting in them having two different annealing properties. 
The 5’end fragment in the DPO system is longer (18-25 nucleotides) than the 3’end fragment 
(6-12 nucleotides) and the linker is 3 to 8 deoxyinosines long (Figure 1.7). 
 
Figure 1.7: The structure of DPO. The 5’end portion (B) is longer than the 3’ end portion (A). The 
polydeoxyinosine linker is not involved in the priming process and forms a bubble-like structure at high 
temperatures. Taken from Seegene, (http://www.seegene.com). 
 
Basically, the first step of the reaction involves the linker activation step during which, due to 
its weak hydrogen bonds, the linker conforms a bubble-like shape at a certain temperature, and 
as the result, the initial single primer, changes into two functional priming regions (Figure 
1.8). 
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Figure 1.8: Diagrammatic illustration of the change in shape of the polydeoxyinosine linker into a bubble-like 
shape. The linker has weak hydrogen bonds and as a result, it has a low melting temperature. At high annealing 
temperatures, its hydrogen bonds break resulting in it forming a bubble-like shape. The initial single primer 
changes into two separate entities as a result. Adapted from Seegene, (www.seegene.com, 2008).  
 
The first priming PCR reaction involves preferential binding of the longer priming fragment 
(5’end) to its target region forming a stable structure (Figure 1.9). 
 
Figure 1.9: Diagrammatic illustration of the first priming PCR reaction involving DPO. The longer 5’end region 
acts as a stabilizer and binds preferentially to the target region of the template DNA strand forming a stable 
structure. Adapted from Seegene, (www.seegene.com, 2008). 
 
During the second priming PCR reaction, the shorter priming fragment (3’end) takes part in 
target-specific extension during which it selectively binds to the target site, thus acting as a 
determiner (Figure 1.10). 
The difference between the DPO and conventional priming systems is that a single priming 
event occurs between primer and template in the conventional system as opposed to the DPO 
system where two priming events take place due to two separate primer fragments (Figure 
1.11).  
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Figure 1.10: Diagrammatic illustration of the second priming PCR reaction involving DPO. The shorter 3’end 
region determines target-specific extension by selectively binding to the template DNA strand. It therefore acts as 
a determiner. Adapted from Seegene, (http://www.seegene.com). 
 
In these two priming events, although the longer 5’-segment binds a non target site, the shorter 
3’-segment resists non-specific extension. Because of this aspect, the DPO technology 
eliminates extension of non-specifically primed templates generating high PCR specificity 
even if PCR conditions are below optimum (Chun et al., 2007).  
 
 
Figure 1.11: Difference in conventional and DPO priming systems. A perfect match between the primers and the 
target in both priming systems results in extension. Any sort of mismatch either in the 3’end or 5’end of 
conventional system will still result in extension in the conventional priming system but not in the DPO system. 
Adapted from Chun et al (2007). 
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In real-time PCR, primer extension may proceed even in the presence of mismatches between 
a primer and a template. In the contrary, extension in the DPO system only proceeds when 
there is a perfect match between the two priming fragments and the template (Figure 1.11, 
perfect match). Even supposing the 5’-segment which initiates stable annealing binds to the 
template, any mismatch in the 3’-segment will result in no extension (Figure 1.11, mismatch at 
3’end). A mismatch at the 5’-segment will mean that due to the low Tm of the short 3’-segment 
(below 30oC), it is unable to anneal at the high reaction temperatures of 55-65oC, thus no 
extension will occur (Figure 1.11, mismatch at 5’end).  
 
Multiplex PCR detection kits that apply the DPO system were used in conjunction with real-
time PCR in this study to detect respiratory pathogens in patient samples. 
 
1.8. Brief description of organisms to be investigated 
Ten viruses, 4 bacteria, 1 fungus and 2 internal controls were selected to be studied in this 
project. In this section, various aspects of the organisms ranging from their taxonomy 
(classification and structure), pathogenesis, effects of the disease they cause in adults as well 
as the respective genes targeted in the real-time PCR reactions performed, will be briefly 
discussed. 
 
1.8.1. Viruses 
As electron microscopy became a more widely available tool, the morphology of the virus 
particle (Figure 1.12) became a key feature for virus classification (Buchen-Osmond, 2003).  
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Figure 1.12: Morphology of human viral pathogens and the families they belong to. Abbreviations in pink: EBV 
(Epstein-Barr virus), CMV (cytomegalovirus), AdV (adenovirus), PIV (Parainfluenza virus), RSV (respiratory 
syncytial virus), hMPV (human metapneumovirus), FluA (Influenza A virus), FluB (Influenza B virus). Adapted 
from Buchen-Osmond (2003). 
 
1.8.1.1. Influenza (Flu) A and B viruses  
Classification and structure 
Influenza viruses are a member of the family Orthomyxoviridae and contain a segmented, 
linear, single- stranded, negative-sense RNA genome. They are enveloped viruses with a 
helical symmetry and are 80-120nm in diameter. The RNA is closely associated with the 
nucleoprotein (NP) to form a helical structure. The Influenza genus is divided into three types, 
A, B and C, based on epitopes on the internal nucleoprotein and the M protein. Human 
influenza A virus strains are further classified in the subtypes H1N1, H3N2 and the presently 
not circulating H2N2 subtype, based on the antigenic differences of the hemagglutinin and the 
neuraminidase surface proteins shown in figure 1.13 (Claas et al., 1992). There are life-
threatening implications of the predicted seasonal occurrence of influenza virus infections, 
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thus, there is a need for rapid and accurate identification of both influenza A and B virus 
genotypes. This provides an opportunity for intervention with effective antiviral treatment if 
provided to the patient in the early stages of this viral disease (Espy et al., 2006) 
 
Pathogenesis 
Respiratory droplets spread the viral infection. The viral particles attach to cells of the 
respiratory epithelium which are rich in viral receptors. The neuraminidase recognition probe 
on the virus particles initiates the infectious process by releasing virus particles bound by 
mucous present on the surface of the epithelial cells. Incubation period of the virus is 1-4 days 
(Wat, 2004). 
 
Effect of disease in adults 
Following an incubation period of 48 hours, the typical symptoms of influenza present as 
fever, photophobia, headache, dry cough and myalgia. The fever is continuous and lasts 
approximately 3 days. 
 
Target gene for real-time PCR: 
FluA - Non-structural protein gene: Non-structural protein of influenza A virus, contributes 
to its pathogenicity and virulence. It is a multifunctional protein that plays a major role in 
resisting the host antiviral response during the influenza infection (Lin et al., 2007). 
FluB - Nucleoprotein gene: The nucleoprotein is the major protein component of the 
ribonucleoprotein core of influenza virions and is a type-specific antigen defining influenza 
viruses as either type A or B (Rota et al., 1990). 
Chapter 1: Introduction 
 22 
 
Figure 1.13: Diagrammatic representation of Influenza virus. Hemagglutinin and neuraminidase spikes are 
embedded in the lipid bilayer. Taken from Ackermann and Berthiaume (1995). 
 
1.8.1.2. Human metapneumovirus (hMPV) 
Classification and structure 
Taxonomically, hMPV is the first human pathogen placed in the Metapneumovirus genus, the 
Paramyxoviridae family and the subfamily Paramyxovirinae (Mejias et al., 2004). This 
classification scheme is based on the organization of the viral genome, morphologic criteria, 
the viral RNA genomic sequence relationships of the encoded proteins and the biologic 
activities of the virus-encoded proteins (Domachowske, 2003). 
 
The hMPV has a pleomorphic, enveloped virion with an average diameter of approximately 
200nm. It contains a single-stranded negative-sense, nonsegmented RNA (13.3kb) that forms a 
helical nucleocapsid, and has surface glycoproteins and projections (Peret et al., 2002; van den 
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Hoogen et al., 2002).  It is termed human metapneumovirus because it does not have the 
ability to infect chickens or turkeys, making it an unlikely zoonotic source (Mejias et al., 
2004). 
 
This virus differs from the human respiratory syncytial virus (hRSV), another paramyxovirus 
by virtue of a lack of two non-structural proteins (NS1 and NS2) and by a slightly different 
gene order for the other common genes, i.e., the phosphoprotein (P), nucleoprotein (NP), 
matrix (M), polymerase (L), fusion (F), small hydrophobic protein (SH), and attachment 
glycoprotein (G) (van den Hoogen et al., 2002). The NP, F, L, and M genes are the most 
conserved and the G and SH genes being the least conserved (Biacchesi et al., 2003). 
 
Pathogenesis 
Little direct experimental work has been reported on the mechanisms of pathogenesis in 
humans. Clinical manifestations of hMPV, ranging from mild-to-severe bronchiolitis and 
occasionally pneumonia, resemble those of RSV (Mejias et al., 2004). Using animal models, 
the virus has been shown to replicate in both the upper and lower respiratory tract, but the 
particular cell types that are affected have not been defined (Crowe 2004, Hamelin and Boivin, 
2005). 
 
Formal transmission studies have not been reported, although the mode of transmission is 
almost undoubtedly large particle respiratory secretions and fomites, based on the relatedness 
of this virus to other pneumoviruses (Crowe, 2004). Nosocomial transmission does occur, 
suggesting that contact isolation and thorough hand washing by health care providers is 
necessary in the hospital or office setting (Esper et al., 2003). 
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Effect of disease in adults 
Several reports have linked hMPV with acute respiratory tract infections in all age groups, 
with more severe diseases occurring in young children, elderly individuals and 
immunocompromised hosts (Hamelin and Boivin, 2005). The clinical symptoms include 
severe cough, high fever, difficulty breathing or abnormally rapid breathing and wheezing. 
These symptoms are indistinguishable from those in a RSV infected individual (Boivin et al., 
2003); however the most commonly reported diagnosis associated with hMPV infection is 
bronchiolitis, with or without pneumonitis. Associations with acute wheezing and asthma 
exacerbation have also been reported (Hamelin and Boivin, 2005). 
Naturally acquired infection does not seem to protect against re-infection (Crowe, 2004). 
However it is possible that infection does stimulate partial protection against severe disease, 
because most serious lower respiratory tract illnesses occur in the first year of life (Williams et 
al., 2004). 
 
Target gene for real-time PCR 
Nucleoprotein (NP) gene: Protection of viral RNA 
 
1.8.1.3. Parainfluenza viruses (PIV) 1-3  
Classification and structure 
Parainfluenza viruses are from the family Paramyxoviridae and subfamily Paramyxovirus. 
They are relatively large enveloped viruses (150-300nm) with a pleomorphic or spherical 
shape. They contain helical RNA that is negative-sense, unsegmented and single-stranded 
(Buchen-Osmond, 2003). They have an RNA-dependent polymerase complex that contains 3 
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non-structural proteins that are tightly associated with the RNA: Nucleoprotein, 
phosphoprotein and large protein. 
 
Pathogenesis 
PIV initially colonises nasopharyngeal mucosa before infecting the respiratory epithelium. 
Firstly, the virus attaches to the host cell sialic acid receptors via the hemagglutinin-
neuraminidase glycoprotein it possesses (Figure 1.14) and spreads to the lower respiratory 
epithelium in 1-3 days. The incubation period is usually 3-10 days and most infections are 
asymptomatic (Wat, 2004). Transmission occurs via fomites and aerosols of respiratory 
secretions. Re-infections are clinically less severe and most commonly involve the upper 
respiratory tract and occur throughout life (Henrickson, 2003). 
 
Effect of disease in adults 
Air-sampling experiments have revealed that PIV1 could be recovered from only 2 of 40 
infected children at a distance of 60 cm (McLean et al., 1967) thus transmission is unlikely to 
take place by small-particle aerosol spread. Additionally, spread of PIV by direct hand contact 
from one individual to the next also appears to be an unlikely means of transmission because 
an experiment has demonstrated that PIV3 placed on fingers loses more than 90% of its 
infectivity in the first 10 minutes (Ansari et al., 1991). PIV1, 2 and 3 have all been shown to 
survive for up to 10 hours on nonporous surfaces and 4 hours on porous surfaces (Brady et al., 
1990) thus contaminated surfaces might then result in direct self-inoculation (Hall and 
Douglas, 1981).  
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Target gene for real-time PCR:  
PIV 1, 2 and 3 - Hemagglutinin-neuraminidase (HN) gene: Parainfluenza viruses display 
two surface glycoproteins; namely, the haemagglutinin-neuraminidase (HN) and the fusion 
protein (F) (Figure 1.14). HN has three functions: (i) a receptor-binding (haemagglutinin) 
activity; (ii) a receptor destroying (neuraminidase) activity that liberates terminal sialic acid 
(N-acetyl neuraminic acid, Neu5Ac) residues from glycol-conjugates; and (iii) a fusion 
activating activity operating via an as yet undefined mechanism believed to involve an 
interaction of HN with the F protein (Hall, 2001). 
 
 
 
Figure 1.14: Structure of parainfluenza virus and respiratory syncytial virus. Taken from Hall (2001). 
 
1.8.1.4. Respiratory syncytial virus (RSV)  
Classification and structure 
RSV is an enveloped negative-sense RNA virus that is a member of the family 
Paramyxoviridae and classified within the genus Pneumovirus. Its genome is nonsegmented 
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and single-stranded and is composed of approximately 15 222 nucleotides (Collins et al., 
1996). It is pleomorphic and is 150-300nm in size. The structure of RSV is shown in figure 
1.14. 
 
Pathogenesis 
After a 2 to 8 day incubation period, the RSV virus replicates in the nasopharyngeal 
epithelium and spreads to the lower respiratory tract 1 to 3 days later. The distinctive 
inflammation of RSV bronchiolitis is necrosis and sloughing of the epithelium, with edema, 
and increased mucus secretion, which obstructs flow in the small airways (Hall, 2001).The 
manifestations of RSV may be difficult to distinguish from those of other respiratory viruses; 
however, there are symptoms which may suggest RSV. A typical RSV illness begins with 
nasal congestion and discharge and this helps distinguish RSV from influenza (Mathur et al., 
1980). Cough is common and affects 90 to 97% of patients. Fever is observed in 50% of 
patients as opposed to 75% with influenza virus or bacterial infections (Falsey et al., 1995). 
Although temperatures of 39 to 40oC are frequently observed, fevers are usually lower than in 
influenza (Falsey and Walsh, 2000). 
 
Transmission of RSV occurs by direct inoculation of infectious respiratory secretions from the 
hands or by large-particle aerosols into the eyes and nose, but rarely the mouth (Wat, 2004). 
 
Effect of disease in adults 
Excretion of RSV from infected adults averages 3 to 6 days, but may occur over 1 to 12 days. 
RSV is spread primarily by fomites and large droplets and can survive on nonporous surfaces, 
skin and gloves for several hours thus person-to-person contact or contact with contaminated 
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surfaces is required for transmission. The virus is not stable when aerosolized thus small 
particle aerosols are not considered a main mode of transmission (Falsey and Walsh, 2000). 
 
Target gene for real-time PCR:  
Non-structural protein 1: Function is to antagonise interferon-induced antiviral response 
(Hacking and Hull, 2002). 
 
1.8.1.5. Adenovirus (AdV) 
Classification and structure 
Adenoviruses (Genus Mastadenovirus, Family Adenoviridae) are ubiquitous pathogens of both 
animals and humans. They are isometric in shape, 70-90nm in size and have linear double-
stranded DNA. They possess a nucleocapsid that has an icosahedral symmetry (Buchen-
Osmond, 2003).  
 
To date, 51 different human adenovirus serotypes, organised into six major subgroups 
(subgenera or species A-F), have been identified based on their oncogenic, morphologic, 
hemagglutinating and DNA sequence properties as well as their responses to neutralizing 
antibodies (Horwitz, 2001). 
 
Pathogenesis 
They cause a variety of diseases ranging from respiratory illnesses, encephalitis, cystitis and 
keratoconjunctivitis to gastroenteritis and can be recovered from most parts of the body 
affected by the infection (Ko et al., 2005). However, adenovirus infections in 
immunocompromised patients tend to become invasive and disseminated disease is associated 
with very high mortality rates (Ebner et al., 2005). The incubation period is in the range of 4–7 
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days, but could be as long as 2 weeks and its mode of transmission is airborne or by direct 
contact with self-inoculation (Wat, 2004). 
 
Effect of disease in adults 
The duration of excretion of adenovirus ranges from 2 to 12 months in immunocompromised 
patients (throat, urine, stool, organ biopsies), 3 to 6 weeks in children with respiratory or 
generalized illnesses (throat , stool), 2 weeks in adults with keratoconjunctivitis (eye) and 3 to 
5 days in patients with pharyngoconjunctival fever (eye, ear, nose, throat, urine, stool) or 
central nervous system  symptoms (cerebrospinal fluid), to 1 to 3 days in adults with common 
colds (throat). It is therefore necessary to be able to identify adenoviruses in any clinical 
specimen without regard to the type of specimen or the amount of virus present (Hierholzer et 
al., 1993). 
 
Currently available treatment options, which include antiviral agents such as cidofovir and 
ribavirin, immunomodulation, and more recently, cytotoxic T cells, have been reported to 
work successfully at least in a proportion of patients thus emphasizing the importance of 
adequate diagnostic techniques permitting timely detection and monitoring of the course of 
infection (Ljungman, 2004). Molecular methods such as PCR and probe hybridization have 
been used to detect pathogenic microorganisms, including adenoviruses, because the methods 
are rapid, sensitive, and specific (Xu et al., 2000).  
 
Target gene for real-time PCR: 
Hexon gene: This gene codes for one of the structural proteins in the viral coat and is 
synthesized during late infection (Pring-Akerblom et al., 1995). 
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1.8.1.6. Cytomegalovirus (CMV)  
Classification and structure 
CMV is a viral genus of the Herpesviridae group. It belongs to the Betaherpesvirinae 
subfamily of Herpesviridae. It is spherical in shape, has an icosahedral symmetry and is 
150nm in size. It has linear double-stranded DNA that is monopartite (Buchen-Osmond, 
2003). 
 
Pathogenesis 
All herpesviruses share a characteristic ability to remain latent within the body over long 
periods. CMV infections are frequently associated with salivary glands though they may be 
found throughout the body. Some people infected with CMV develop an infectious glandular-
like syndrome with prolonged fever and a mild hepatitis. A sore throat is common. After 
infection the virus remains latent in the body for the rest of the person’s life and evident 
disease rarely occurs unless immunity is suppressed by infection, drugs or old age. 
Transmission of CMV occurs from person to person through bodily fluids. Infection requires 
close contact with a person excreting the virus in their saliva, urine, blood, tears, semen or 
breast milk. 
 
Effect of disease in adults 
Initial infection with CMV typically causes no symptoms. The virus continues to live in the 
body silently without causing obvious damage or illness. It seldom becomes active for the first 
time unless the immune system weakens and is no longer able to hold the virus in check. 
Active infection in both children and adults causes chills, severe tiredness, prolonged high 
fever, headache, and an enlarged spleen. In severe cases, CMV infection can cause 
pneumonia, anaemia, gastrointestinal and liver infection. 
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Target gene for real-time PCR:  
Major immediate-early region: The major immediate-early gene region of human 
cytomegalovirus plays a major role in affecting activation and repression of cellular and viral 
genes. This gene intimately associate and/or interact with viral and cellular proteins 
throughout this process (Stenberg, 1996). 
 
1.8.1.7. Epstein-Barr Virus (EBV)  
Classification and structure 
EBV is a member of the Herpesviridae, the only human virus in the subfamily 
Gammaherpesvirinae. It is a ubiquitous human B-lymphotropic herpesvirus that is spherical, 
150-200nm in diameter and has circular, double-stranded DNA of approximately 172kbp in 
size (Buchen-Osmond, 2003). 
 
Pathogenesis 
EBV infects more than 90% of the world's population and establishes a lifelong (usually 
asymptomatic) persistent infection in its host. It has been estimated that the number of EBV-
infected B cells is controlled in healthy individuals by EBV-specific immunity (Wagner et al., 
1992). EBV is characterised by a primary infection that generally occurs in a sub-clinical 
fashion in early childhood, with subsequent lifelong latent infection. At any time following 
initial infection, reactivation may occur. Reactivation of EBV may be severe and even life-
threatening in immunocompromised individuals such as bone marrow and solid-organ 
transplant recipients and in AIDS patients. Therefore, early diagnosis of EBV infections is 
important in the management of high-risk patients (Jebbink et al., 2003). Several malignancies 
have been associated with EBV infections especially in immunosuppressed patients who lack 
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antibodies to the virus. EBV associated malignancies can occur in the central nervous system 
especially in HIV patients (Espy et al., 2006). The virus is transmitted primarily by saliva and 
transmission by blood transfusion is rare. 
 
Effect of disease in adults 
When infection with EBV occurs during adolescence or early adulthood, there is a 35-50% 
chance that glandular fever will develop after an incubation period of 4-6 weeks. Other 
common symptoms are sore throat and lymphadenopathy. EBV is linked to the development 
of several malignant tumours including Burkitt’s lymphoma, some forms of T cell lymphoma, 
Hodgkin’s disease and undifferentiated nasopharyngeal carcinoma. 
 
Target gene for real-time PCR:  
RPMS1 protein: RPMS1 is an open reading frame that encodes a nuclear protein termed 
RPMS. This open reading frame is contained in one of the BamHI rightward transcripts that 
are expressed in all EBV-associated tumors. RPMS1 acts as an antagonist of Notch signalling 
(Zhang et al., 2001). 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 33 
1.8.2. Bacteria 
Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila have emerged as 
an important cause of respiratory tract infections, accounting for between 15 to 50% of CAP 
(Sopena et al., 1999).  
 
 
1.8.2.1. Chlamydia pneumoniae and Chlamydia psittaci 
Classification and structure 
Chlamydia pneumoniae and Chlamydia psittaci belong to the family Chlamydiaceae and the 
genus, Chlamydophila. At one point, the Chlamydiaceae were thought to be viruses because 
they are small enough to pass through 0.45µm filters and are obligate intracellular parasites, 
however, they also have the following characteristics of bacteria: (1) they contain both 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA); (2) they possess inner and outer 
membranes similar to those of gram-negative bacteria; (3) they manufacture their own 
proteins; (4) they are susceptible to various antibiotics; and (5) they possess prokaryotic 
ribosomes (Murray et al., 2005). Chlamydiaceae, unlike other bacteria, have a unique 
developmental biphasic growth cycle whereby they form elementary bodies which are the 
metabolically inactive infectious forms (extracellular) and reticulate bodies, which are the 
metabolically active non-infectious forms (intracellular) (Hahn et al., 2002).  
 
Chlamydia pneumoniae is an ubiquitous, obligate, intracellular bacterium associated with a 
wide variety of acute and chronic diseases. Chlamydiae multiply within membrane-bound 
vacuoles in eukaryotic host cells but are incapable of generating adenosine triphosphate (ATP) 
and thus are dependant on the host cell ATP deposits for all energy requirements. In addition, 
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they are incapable of de novo nucleotide biosynthesis and are thus dependent on host 
nucleotide pools (Cosentini et al., 2001). 
 
Pathogenesis 
Chlamydia inflicts damage by causing the release of antigen onto epithelial cell surfaces that 
stimulate host immune (inflammatory) responses and ciliostasis (Shemer-Avni and Lieberman, 
1995). The organism also infects alveolar macrophages, although it is almost certainly 
incapable of establishing productive infections in these cells (Hahn et al., 2002). 
It is transmitted from person to person via respiratory droplets and has an incubation period of 
7-21 days (Grayston et al., 1990). 
 
C. psittaci is the cause of psittacosis (parrot fever) which can be transmitted to humans from 
parrots. The natural reservoir of C. psittaci is virtually any species of birds, mostly psittacine 
birds (e.g., parrots, parakeets, macaws) and the bacterium is usually transmitted to humans 
through inhalation of urine, respiratory secretions or dried bird excrement. Person-to-person 
transmission is rare. Illness develops after an incubation of 5 to 14 days (Murray et al., 2005). 
 
Effect of disease in adults 
C. pneumoniae causes acute respiratory disease including pneumonia, bronchitis, sinusitis and 
pharyngitis (Gouriet et al., 2006). Initial symptoms most frequently reported by patients with 
C. pneumoniae are sore throat and hoarseness and a dry persistent cough often sets in after a 
period of up to a week (Grayston et al., 1990). Although PCR holds a promise as a rapid 
diagnostic test for C. pneumoniae infection, serological testing remains the most commonly 
used method (Kumar and Hammerschlag, 2007). 
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Infection by C. psittaci occurs by means of the respiratory tract, after which the bacteria 
spread to the reticuloendothelial cells of the liver and spleen. Symptoms range from headache, 
high fever, chills and malaise. Patients may also experience gastrointestinal tract symptoms 
such as diarrhoea, nausea and vomiting. Untreated cases may result in death (Murray et al., 
2005). 
 
Target gene for real-time PCR 
C. pneumoniae - 16S ribosomal RNA gene: This is a highly conserved region in the 
Chlamydiaceae family. This gene contains conserved and variable regions according to their 
taxonomic genetic stability. Organisms can be classified into different taxonomy levels based 
on variations of DNA sequences in these regions. Organisms within a domain frequently share 
the same DNA sequence in the most conserved region, while species of the same genus may 
be distinguished using the DNA sequence in the variable regions (Woese et al., 1990). 
C. psittaci - Outer membrane protein (OmpA) gene: OmpA genes encode the cysteine-rich 
major outer membrane protein (MOMP). MOMP has a function in immunogenicity and 
potential function as a cellular adhesion (Millman et al., 2001). 
 
1.8.2.2. Mycoplasma pneumoniae 
Classification and structure 
Mycoplasma pneumoniae is the smallest of all free-living organisms (10 x 200nm), stains 
Gram negative, appears filamentous, does not possess a peptidoglycan wall, and is bounded 
instead by a sterol triple-layered plasmic membrane (Gleason, 2002). It displays a neuraminic 
acid receptor site for attachment to host cell membranes (Cosentini et al., 2001).  
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The lack of a cell wall has been linked to atypical biochemical, cultural and serological 
behaviour, distinct pleiomorphism, and from a clinical perspective, resistance to antibiotics 
that hinder cell wall synthesis. It is taxonomically separate from bacteria and belongs to the 
class Mollicutes. It is a slow growing, pleiomorphic, nonmotile, aerobe that ferments glucose 
(Cosentini et al., 2001). 
 
Pathogenesis 
M. pneumoniae is a frequent causative agent of CAP and lower respiratory tract infections 
(LRTI) in children and young adults (Templeton et al., 2003) ranging from mild to life-
threatening infections. M. pneumoniae attaches to the respiratory epithelium, acquiring 
essential exogenous nutrients for growth. It may become intracellular (Baseman and Tully, 
1997). Additionally, it produces hydrogen peroxide and superoxide, causing injury to 
epithelial cells and associated cilia. This damage to the epithelial layer likely facilitates co-
infection with other pathogens.  
 
M. pneumoniae can be transmitted through aerosol droplets or nasal secretions from person to 
person after exposure to an acutely ill coughing individual. The incubation period ranges from 
2 to 4 weeks (Gouriet et al., 2006). After attaching to epithelial cells by means of its 
neuraminic differentiated terminal unit, M. pneumoniae disrupts cell RNA and protein 
synthesis, resulting in inflammatory cell recruitment, ciliostasis, denaturation of cilia and 
extensive epithelial cell injury  (Cosentini et al., 2001).  
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Effect of disease in adults 
Infection caused by M. pneumoniae usually mimics viral respiratory syndrome. The most 
common manifestations include sore throat, hoarseness, fever, a non-productive cough, 
headache, chills, coryza, myalgias and general malaise. Since this organism is not sensitive to 
β-lactam antibiotics which are often used for the empirical treatment of LRTI, a rapid 
diagnostic method is required for the prescription of effective antibiotics (Hardegger et al., 
2000). 
 
Target gene for real-time PCR 
Cytadhesin P1 protein: The protein is the major adhesin mediating the attachment of this 
mycoplasma to respiratory epithelium (Yang et al., 2002). 
 
1.8.2.3. Legionella pneumophila 
Classification and structure 
The genus Legionella includes about 40 different species of thin, nonspore-forming, 
pleiomorphic, uncapsulated, aerobic, gram-negative bacilli, with more than 60 described 
serogroups. Legionella is rich in ramified fatty acids and thrives in water reservoirs (Cosentini 
et al., 2001). Within the species L. pneumophila there are 15 serogroups, with serogroups 1 
being commonly found clinically and the only serogroup identified by the commercially 
available urine antigen test for Legionella (Gleason, 2002). They are fastidious organisms and 
only grow on specialised media (Gouriet et al., 2006).  
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Pathogenesis 
Legionella can replicate intracellularly within respiratory monocytic cells and invoke their 
damage by inhibiting phagocyte-liposome fusion. Risk factors for infection with Legionella 
include advanced age, alcoholism, cigarette smoking, chronic disease, immunosuppression 
and organ transplantation (Marston et al., 1994). 
 
Effect of disease in adults 
Available data indicate that the most likely mode of transmission is direct inhalation from 
Legionella-contaminated water supply systems. Patient isolation is not required as no person-
person transmission has been reported. The incubation period ranges from 2 to 10 days. Most 
patients report high fever (>40oC) and dry cough (Cosentini et al., 2001). In 
immunocompromised patients, pneumonia produced by Legionella can result in a fatal 
outcome in up to 50% of cases (Yu, 2000). The vast majority of such cases (up to 85%) are 
caused by L. pneumophila, the most common pathogenic species of the Legionella genus 
(Cosentini et al., 2001).  
 
Target gene for real-time PCR:  
Macrophage infectivity potentiator (mip) gene: The mip gene sequences of Legionella 
species code for an immunophilin of the FK506 binding protein (FKBP) class and belongs to 
the enzyme family of peptidylprolyl cis/trans isomerases (Hacker and Fischer, 1993). This 
protein, which ranges in size from 232 to 251 amino acids, depending on the Legionella 
species (Ratcliff et al., 1997), is an outer membrane protein essential in the intracellular cycle 
of Legionella. The reason for targeting the mip gene of L. pneumophila is because the gene 
encodes a macrophage infectivity potentiator and is identified only in L. pneumophila 
(Morozumi et al., 2006). 
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1.8.3. Fungi 
1.8.3.1. Pneumocystis jirovecii  
Classification and structure 
Pneumocystis jirovecii is an ascomycetous fungus that causes opportunistic infections, 
predominantly pneumonia, in patients with weakened immunity due to HIV, transplantation, 
malignancy and connective tissue disease (Miller and Huang, 2004). This organism was first 
called P. carinii after it had been identified in rat lungs by Antonio Carinii in 1910 (Thomas 
and Limper, 2007). Based on the histological characteristics of its trophozoite and cyst life 
forms, it was classified as a protozoan. However, in 1988, P. carinii was placed into the fungal 
kingdom after sequencing of the small ribosomal RNA subunit (Edman et al., 1988). Since its 
discovery, every mammal has been shown to possess a unique form of Pneumocystis with 
different genetics and strong host specificity. The form that infects humans has been named P. 
jirovecii after Jirovec, the pathologist who first reported it in humans (Stringer et al., 2002). 
Study of the organism has been severely hindered by the fact that it cannot be cultured in vitro 
(Thomas and Limper, 2004). 
 
Pathogenesis 
The route by which human Pneumocystis is transmitted is unclear. It’s DNA has been 
identified in air spores from both rural and hospital environments, and it is possible that 
transmission between humans occurs via the airborne route (Miller et al., 2001). Studies have 
shown a decline in the number of AIDS-related opportunistic infections attributed to the use of 
highly active antiretroviral therapy (HAART), increasing use of HIV prophylaxis, and 
improved awareness of this infection (Pulvirenti et al., 2003). 
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Serologic studies have resulted in the detection of specific antibodies to the pathogen in most 
children early in life (Medrano et al., 2003) and based on this finding, disease in 
immunocompromised patients has been thought to result from reactivation of latent infection 
acquired in childhood. This “latency” hypothesis has been disputed by studies showing a lack 
of Pneumocystis in the lungs of healthy humans (Wakefield et al., 1990) and by studies which 
showed that Pneumocystis organisms are frequently acquired and cleared by the immune 
system of immune competent individuals (Miller et al., 2001). 
 
In the last 10 years, PCR has considerably increased the sensitivity of detection of 
Pneumocystis, to 86-100% in BAL, aspirates, and induced sputum specimens (Flori et al., 
2004). However, one problem with the technique is that it is frequently positive (2-21%) in 
patients with asymptomatic carriage (Maskell et al., 2003). Real-time PCR could have a role 
in distinguishing between colonization and clinical disease with the application of threshold 
cutoff values as described by Larsen et al., (2002). P. jirovecii patients would have a higher 
organism’s burden than colonised patients indicated by the threshold values obtained form the 
real-time PCR fluorescence curves generated. 
 
Effect of disease in adults 
Typical symptoms of pneumocystis pneumonia include the subtle onset of progressive 
dyspnea, nonproductive cough or cough productive of clear sputum, malaise, and low-grade 
fever (Thomas and Limper, 2004). These symptoms are amplified in HIV-infected patients 
with them often presenting with a higher arterial oxygen tension and a lower alveolar-arterial 
oxygen gradient (Krajicek et al., 2008). 
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Target gene for real-time PCR 
Mitochondrial large subunit rRNA (mtLSU rRNA) gene: The mtLSU rRNA gene is 
implicated in basic metabolic functions and this is the locus used most extensively for PCR-
based detection of P. jirovecii, as it is present in a large number of copies (Esteves et al., 
2008). 
 
1.8.4. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
GAPDH is a tetramer composed of four identical 37 kDa monomers (Sirover, 1996). It can be 
used as an endogenous control i.e. a template that occurs naturally within the specimen being 
examined which in this case is human. GAPDH has vital functions in mammalian cells as 
shown in Table 1.1 and therefore will always be present in human tissue. Housekeeping genes 
have been used successfully to quantitate gene expression by real-time PCR and monitor the 
integrity of a template for quantification and other purposes (Chehab et al., 1987). 
 
Table 1.1: Functions performed by GAPDH in mammalian cells. Adapted from Sirover, (1996). 
 
 
CELL FUNCTION 
INTRACELLULAR 
LOCALIZATION 
 
ACTIVITY 
Macromolecular transport Cytoplasm Endocytosis 
Energy generation Cytoplasm Glycolysis 
Control of gene expression Cytoplasm, Nucleus Regulation of translation 
Prevention of genomic instability Nucleus Repair of DNA molecules 
Transfer of genetic information Nucleus Replication of DNA 
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1.9. Statement of the problem  
The diagnostic capacity of the classical microbiology laboratory in the routine identification of 
the causative organisms in patients with CAP has limitations. Culture of samples typically 
requires several days and an isolated pathogen is documented in less than 50% of patients with 
CAP (Stralin et al., 2006). Since CAP is a serious infection, antimicrobial treatment cannot be 
delayed while awaiting microbiological identification of the etiological agents. Empiric 
antimicrobial therapy must be initiated based on clinical symptoms, radiographic and other 
laboratory findings.   
 
Recent studies (Templeton et al., 2005; Morozumi et al., 2006) have shown that real-time 
PCR assays are more sensitive for the detection of the major viral, typical and atypical 
bacterial causative agents of CAP than standard microbiological methods. Since the spectrum 
of organisms in an area will define which diagnostic tests and treatment should be offered, it is 
essential to establish the most common causative agents of CAP in the selected population. 
Routine investigation of sputum specimens for diagnosis of CAP is not currently regarded as a 
rational approach, but the periodic surveillance of etiological organisms in an area should 
result in more informed treatment decisions being made.  
` 
1.10. Justification of the study 
There remains much that is still unknown regarding the etiology of CAP in South Africa. Data 
from prospective studies are restricted to a few European countries, with most performed in 
the UK and Spain and few on the African continent (Woodhead, 2002). Since early 
intervention with appropriate antibiotics has been shown to decrease mortality and 
transmission of infection, knowledge of the most likely agents to cause CAP at the Charlotte 
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Maxeke Johannesburg Hospital should improve the care of patients with CAP at this facility. 
(Moine et al., 1994; Leroy et al., 1995). There is therefore a need to establishment sensitive 
and rapid pathogen detection methods to reduce the potential of nosocomial transmission to 
high-risk patients such as neonates and direct appropriate therapy following specific pathogen 
detection. 
 
Real-time PCR in conjunction with multiplex PCR kits employing the DPO technology were 
the molecular methods used in this study to detect a panel of respiratory viruses that literature 
has suggested as common causative organisms of CAP. These methods have been proved in 
other studies to have increased sensitivity, throughput and quantitative potential.  
 
Real-time PCR has been described for a variety of clinical applications, namely genotyping, 
mRNA quantification and pathogen detection just to mention a few. For pathogen detection, 
this technique has been found to be reproducible (Loeb et al., 2000) and accurate when using 
TaqMan probes (Desjardin et al., 1998). TaqMan assays have proved to be much more 
sensitive than culture methods (Schweiger et al., 2000) and ELISA-based assays (Guiver et 
al., 2000).  
 
The multiplex PCR kits that employ DPO technology have also been validated for the 
detection of respiratory pathogens (Chun et al., 2007). The DPO technology does not suffer 
from any limitations of annealing temperature. Because the long DPO primer is divided into 
two target specific priming regions by the linker, the segments have distinct priming functions 
and non-target amplification is eliminated.  
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1.11. Objectives 
1.11.1. Overall Objective 
The primary objective of this study was to establish molecular methods for the detection of atypical 
bacterial, fungal and viral etiological agents that could be used to study their prevalence locally. 
 
The specific objectives of this study were to:  
1.11.2. Specific Objectives 
• To establish a nucleic acid extraction method for isolation of both DNA and RNA from patient 
sputa and nasopharyngeal swabs, that permits downstream PCR analysis. 
• To establish methods for the rapid, qualitative detection of: Mycoplasma pneumoniae, 
Chlamydia pneumoniae, Chlamydia psittaci, Pneumocystis jirovecii, Legionella pneumophila, 
parainfluenza virus (PIV) 1, 2 and 3, adenovirus (AdV), respiratory syncytial virus (RSV), 
influenza virus (Flu) A and B, cytomegalovirus (CMV), human metapneumovirus (hMPV), and 
Epstein-Barr virus (EBV) using the BioRad Chromo4 real-time detection system. 
• To compare results of real-time PCR with those of respiratory pathogen detection kits using 
patient samples and simulations. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
 
All reagents were of analytical or molecular grade. For a complete list of the composition of all 
media and buffers/solutions used, see Appendix A. 
 
2.1.Bacterial, fungal and viral controls 
Positive controls in the form of viral culture supernatants, direct culture and in some cases, 
nucleic acid, of bacteria, fungi and viruses were obtained from the following sources: 
• National Institute for Communicable Diseases (NICD) 
• University of Cape Town (Craig Corcoran) 
These laboratories could not provide information on bacterial, fungal or viral loads of the positive 
controls. 
DNA and RNA used for the human internal controls were obtained from buccal swabs. 
 
2.2.Sample collection 
Ethics clearance to allow patient sample collection for this research was obtained from the 
Human Ethics Committee (Medical) with the ethics clearance number M070345 (Appendix F). 
This project is part of a larger CAP etiology study (see ethics clearance certificate), involving 
collection of samples by clinicians at the Charlotte Maxeke Johannesburg Hospital. However, 
due to factors beyond our control, sample collection was sporadic and only 3 samples were 
submitted during 2008. Therefore, for the purpose of method validation, patient samples were 
simulated. Because nasopharyngeal swabs are standard specimens for respiratory viral diagnosis, 
Copan ESwabs (Copan Italia, Brescia, Italy) were used to collect samples from the nasopharynx 
of 3 CAP patients and also used to simulate the collection of a further 2 swabs on which detection 
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of viruses could be performed. Copan ESwabs enable collection and safe transportation of swab 
samples. The Copan ESwab has a nylon flocked applicator intended for the collection of samples 
from the nasopharynx. The swab incorporates a modified Liquid Amies transporting medium 
comprising calcium, inorganic phosphate buffer, and magnesium salts. This medium sustains the 
viability of a number of organisms that are of clinical importance and is free of enzymes and 
inhibitors that may interfere with molecular amplification assays. In addition, it stabilizes 
bacterial and viral antigens and nucleic acids during transit to the testing laboratory. For bacterial 
and fungal detection, sputum samples were collected from the same CAP patients from whom 
nasopharyngeal swabs were collected.  
 
To simulate the conditions of a nasopharyngeal swab, Copan ESwabs were immersed in a 
mixture of 50 µl each FluA, RSV, CMV, PIV1 and PIV2 viral culture (viral load not quantified) 
for a few seconds before the swab was transferred into the liquid Amies medium that was 
supplied with the swabs. Nasopharyngeal swab simulations were done in duplicate. 
 
For sample simulation, sputum samples from cystic fibrosis patients were obtained from 
Charlotte Maxeke Johannesburg Hospital (formally Johannesburg General Hospital). Samples 
from these patients were used since they are collected routinely and not due to clinical suspicion 
of CAP. They were judged to be less likely than clinical specimens to contain the organisms 
under investigation. 
 
2.3.DNA/RNA extraction 
Both RNA (FluA, FluB, RSV, hMPV, PIV1, PIV2, and PIV3) and DNA (EBV, CMV, AdV, P. 
jirovecii, M. pneumoniae, C. pneumoniae, L. pneumophila and C. psittaci) organisms were 
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investigated in this study. Both RNA and DNA reactions were internally controlled using 
GAPDH (DNA) for DNA organisms and GAPDH (RNA) for RNA organisms. The purpose of 
including GAPDH internal controls was to monitor extraction and reaction steps involving both 
DNA and RNA organisms to enable the detection of inhibition. Nucleic acids were extracted 
from the culture supernatants or colonies and patient samples and simulations.  
 
2.3.1. Positive control extraction 
DNA and RNA were extracted from 200 µl of the bacterial, fungal and viral cultures and from 
buccal swabs (GAPDH) using a commercial extraction kit (RTP® DNA/RNAVirus Mini Kit; 
Invitek, Berlin, Germany) according to the instructions of the manufacturer. Briefly, 200 µl of 
cell culture supernatant was mixed with 200 µl of nuclease free H2O and transferred to an 
extraction tube. The mixture was vortexed and incubated in a thermomixer for 15 min at 65oC 
and then for 10 min at 95oC with continuous shaking. Binding solution (400 µl) was added to the 
mixture in the extraction tube and after vortexing, the sample was transferred into a spin filter set. 
The spin filter set was centrifuged for 1 min at 10 600 x g after which 500 µl of wash buffer R1 
was added and centrifuged for 30 sec at 10 600 x g. The filtrate was discarded and the spin filter 
washed with wash buffer R2 (800 µl), and centrifuged at 10 600 x g for 30 sec. Residual ethanol 
was removed by centrifuging the spin filter for 4 min at 14 000 x g. The nucleic acids were eluted 
into a 1.5ml tube by adding 40-50 µl of prewarmed (80oC) elution buffer directly onto the spin 
filter surface, incubating for 3 min at room temperature and centrifuging for 1 min at 10 600 x g. 
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2.3.2. Specimen extraction 
A pre-extraction procedure provided by BioMe´rieux (St. Laurent, Quebec, Canada), specifically 
to make sputum samples more fluid, was applied to all sputum samples. Briefly, equal volumes 
of whole sputum and proteinase K buffer (250 µl each) were added and vortexed. Handling of all 
sputum samples was done under a Biosafety II hood. The mixture was incubated at 55oC for 60 
min, making sure to vortex every 15 min. The complete 500 µl was used for the downstream 
extraction procedure. 
 
The NucliSens miniMAG System (BioMe´rieux, St. Laurent, Quebec, Canada), which uses silica 
extraction technology, was used for the nucleic acid extraction from the all sputum and 
nasopharyngeal swabs following manufacturer’s recommendations. Briefly, lysis buffer was 
centrifuged for 10 sec at 1500 x g before the sample (10-1000 µl) was added to the buffer in the 
lysis buffer tube. Lysis Buffer contains a chaotropic salt for efficient lysis and inactivation of 
nucleases. The mixture was briefly vortexed, incubated at room temperature for 10 min, then 
centrifuged for 10 min at 1500 x g. The silica slurry was vortexed briefly before transferring 50 
µl of it to the mixture in the lysis buffer tube to allow DNA binding. The contents of the lysis 
buffer tube were mixed gently and incubated at room temperature without further mixing. After 2 
min, the lysis buffer tube was centrifuged at 1500 x g for 2 min. Next, the supernatant was 
transferred to a screw cap 1.5 ml tube and the silica particles were washed twice with 400 µl of 
Wash Buffer 1 (guanidine thiocyanate, Tris/HCl, TritonX 100, EDTA) for 30 sec per wash, once 
with 500 µl of Wash Buffer 2 (morpholine-4-ethanesulfonic acid (MES) hydrate) for 30 sec, and 
once with 500 µl of Wash Buffer 3 (component: disodium tetraborate) for 15 sec using the 
NucliSens® miniMAG™ instrument to remove any contaminants from the specimen. The 
removal of wash buffer between each wash step was done by vacuum aspiration. The magnet was 
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activated during the wash steps and when removing the wash buffer. Finally, DNA was recovered 
from the particles by adding elution buffer (25 µl) to the silica and incubating in a thermoshaker 
for 5 min at 60oC shaking at 1400 rpm. The tubes were placed on a magnetic rack and the 
extracted DNA and RNA (25 µl) was transferred by pipetting to a clean storage tube and used for 
real-time PCR amplification.  
 
2.4.Reverse Transcription 
Reverse transcription of RNA was performed using the High Capacity cDNA Reverse 
transcription Kit (Applied Biosystems, Foster City, CA) according to manufacturer’s 
recommendations. Briefly, reverse transcription master mix (10µl) was prepared: 10X RT Buffer 
(2 µl); 25X dNTP Mix (0.8 µl); 10X RT random primers (2 µl); MultiScribe ™ Reverse 
Transcriptase (1 µl); RNase Inhibitor (1 µl); nuclease-free H2O (3.2 µl). An equal volume of 
RNA sample was added to the master mix in 0.2 ml white PCR tubes (Abgene, Surrey, UK) and 
mixed by pipetting up and down. The mixture was briefly centrifuged to settle the contents. The 
tubes were placed into the Chromo4 Thermal cycler system (Bio-Rad, Hercules, USA) and 
incubated at 25°C for 10 min, followed by 37°C for 120 min and 85°C for 5 sec to inactivate the 
enzyme.  
 
2.5.Real-time PCR 
All reactions were initially performed in singleplex using SYBR® Green I (Bio-Rad, Hercules, 
USA) to determine whether the primers and reaction conditions worked. On establishing this, 
singleplex reactions using TaqMan probes (Inqaba Biotech, Pretoria, South Africa and TIB 
MolBiol, Berlin, Germany) were then performed to test the probes and establish appropriate 
primer and probe concentrations.  
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Multiplex reactions were performed thereafter using TaqMan probes to reduce the number of 
total reactions performed. Different master mixes were used for singleplex and multiplex 
reactions. Total volumes of master mixes used were 12.5µl in total reaction volumes of 25µl and 
25µl in total reaction volumes of 50µl. Most reactions were performed in total volumes of 25 µl 
in thin-walled 0.2 ml white PCR tube strips (Abgene, Surrey, UK).  
 
Some of the primers and probes used for the real-time PCR reactions described in this study were 
adapted from literature (Table 2.1 and Table 2.2). GAPDH (RNA) primers were adopted from 
Barber et al., 2005 which were designed such that the majority of primer nucleotides were within 
the exon region of the genome so that only RNA would be amplified and not DNA. Some 
primers and probes were designed using the Beacon Designer Software Program (Biosoft 
International, Strategene, La Jolla, CA, USA) since suitable primers and probes could not be 
found in the literature (Tables 2.1 and 2.2). GAPDH (DNA) primers were designed such that the 
majority of primer nucleotides were within the intron region of the genome so that only DNA 
would be amplified and not RNA.  
 
The factors taken into consideration when designing probes were the length (15 to 35 
nucleotides), G+C content (40 to 60% with more Cs than Gs) and melting temperature (Tm) (5-
10oC higher than that of the primers). In addition, it was ascertained that no self-complementarity 
was present, no G nucleotides were present at the 5’ end to quench the fluorescent signal after 
hydrolysis and no runs of the same nucleotides were present. Primers were designed to amplify 
fragments of sufficiently different sizes to allow them to be distinguished by gel electrophoresis. 
A BLAST search (http://www.ncbi.nlm.nih.gov/blast) was performed to check specificity of the 
sequences of the primers and probes.  
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2.5.1. Primer sequences 
Table 2.1: Primer sequences and final concentrations used for real-time PCR assays and product sizes.  
Primera Primer Sequence Polarity Final 
concentration 
Origin Amplicon 
Size 
FluA Fb 5’ AAAGCGAATTTCAGTGTGAT 3’ + 750 nM 
FluA Rc 5’ GAAGGCAATGGTGAGATTT 3’ - 750 nM 
Templeton 
et al., 
2004 
104bp 
FluB F  5’ GTCCATCAAGCTCCAGTTTT 3’ + 1000 nM 
FluB R 5’ TCTTCTTACAGCTTGCTTGC 3’ - 1000 nM 
Gunson et 
al., 2005 145bp 
MPV F 5’ AACCGTGTACTAAGTGATGCACTC 3’ + 1500 nM 
MPV R 5’ CATTGTTTGACCGGCCCCATAA 3’ - 1500 nM 
Gunson et 
al., 2005 213bp 
PIV1 F 5’ ACCTACAAGGCAACAACATC 3’ + 500 nM 
PIV1 R 5’ CTTCCTGCTGGTGTGTTAAT 3’ - 500 nM 
Templeton 
et al., 
2004 
129bp 
PIV2 F 5’ GCATTTCCAATCTTCAGGACTATGA 3’ + 500 nM 
PIV2 R 5’ ACCTCCTGGTATAGCAGTGACTGAAC 3’ - 500 nM 
Brittain-
Long et 
al., 2008 
90bp 
PIV3 F 5’ CCAGGGATATACTACAAAGGCAAAA 3’ + 500 nM 
PIV3 R 5’ CCGGGACACCCAGTTGTG 3’ - 500 nM 
Gunson et 
al., 2005 101bp 
EBV F 5’ CGGAAGCCCTCTGGACTTC 3’ + 500 nM 
EBV R 5’ CCCTGTTTATCCGATGGAATG 3’ - 500 nM 
Wada et 
al., 2007 90bp 
CMV F 5’ GACTAGTGTGATGCTGGCCAAG 3’ + 500 nM 
CMV R 5’ GCTACAATAGCCTCTTCCTCATCTG 3’ - 500 nM 
Wada et 
al., 2007 201bp 
RSV F 5’ GCAAATATGGAAACATACGTGAACA 3’ + 500 nM 
RSV R 5’ GCACCCATATTGTWAGTGATGCA 3’ - 500 nM 
Brittain-
Long et 
al., 2008 
115bp 
AdV F 5’ GCCGCAGTGGTCTTACATGCACATC 3’ + 500 nM 
AdV R 5’ GCCCCAGTGGTCTTACATGCACATC  3’ - 500 nM 
Brittain-
Long et 
al., 2008 
132bp 
MpneumoF 5’ AAAACAAGGTCCCCGTCGAG 3’ + 500 nM 
MpneumoR 5’ GCTGCAACTGCTCATAGTACAC 3’ - 500 nM 
This study 102bp 
LpneumoF 5’ AGAGTTAGCGGTCGCATTCAG 3’ + 500 nM 
LpneumoR 5’ ATGTGATCTGCAAGTCGAAAAGTC 3’ - 500 nM 
This study 107bp 
CpneumoF 5’ CGGAGCTAACGTGTTAAGTATGC 3’ + 500 nM 
CpneumoR 5’ TAAGGTCCTTCGCGTTGCATC 3’ - 500 nM 
This study 127bp 
GAPDH (DNA) F 5’ GAGAAGTATGACAACAGCCTCAAG 3’ + 500 nM 
GAPDH (DNA) R 5’ TGAGTCCTTCCACGATACCAAAG 3’ - 500 nM 
This study 112bp 
GAPDH (RNA) F 5’ GAAGGTGAAGGTCGGAGTCAAC 3’ + 200 nM 
GAPDH (RNA) R 5’ CAGAGTTAAAAGCAGCCCTGGT 3’ - 200 nM 
Barber et 
al., 2005 71bp 
Cpsi F 5’ TGCAAGACACTCCTCAAAGCC 3’ + 500 nM 
Cpsi R 5’ TGTGCTCGCTATTCTAATTTGCTC 3’ - 500 nM 
This study 102bp 
PjiroF 5’ CTTAAAATAAATAATCAGACTATGTGCGATAAG 3’ + 1000 nM 
Pjiro R 5’ GGAGCTTTAATTACTGTTCTGGGC 3’ - 1000 nM 
Meliani et 
al., 2003 79bp 
 
a
 FluA (Influenza A virus); FluB (Influenza B virus); MPV (human metapnemovirus); PIV1 (Parainfluenza virus 1); PIV2 (Parainfluenza virus 
2); (PIV3 (Parainfluenza virus 3); EBV (Epstein-Barr virus); CMV (Cytomegalovirus); RSV (Respiratory syncytial virus); AdV (adenovirus); 
Mpneumo (M. pneumoniae); Lpneumo (L. pneumophila), Cpneumo (C. pneumoniae); GAPDH (Glyceraldehyde-3-phosphate dehydrogenase); 
Cpsi (C. psittaci); Pjiro (P. jirovecii). 
bF (Forward), cR (Reverse) 
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2.5.2. Probe sequences 
Table 2.2: TaqMan probe sequences and final concentrations used for real-time PCR assays.  
Probe Probe Sequence d Final 
concentration 
Origin 
FluA Probe 5’ FAM-AGGGCTTTCACCGAAGAGGG-BHQ1 3’ 200 nM Templeton et al., 2004 
FluB Probe 5’ HEX-AACGAAGTAGGTGGAGACGGAGG-BBQ 3’ 200 nM Gunson et al., 2005 
MPV Probe 5’ Cy5- CTTTGCCATACTCAATGAACAAAC -BHQ3 3’ 300 nM Gunson et al., 2005 
PIV1 Probe 5’ FAM-CAAACGATGGCTGAAAAAGGGA-BHQ1 3’ 300 nM Templeton et al., 2004 
PIV3 Probe 5’ Cy5.5-TGGATGTTCAAGACCTCCATACCCGAGAAA-BBQ 3’ 300 nM Gunson et al., 2005 
EBV Probe 5’ FAM-TGTACACGCACGAGAAATGCGCC-BHQ1 3’ 300 nM Wada et al., 2007 
CMV Probe 5’ HEX-AGCCTGAGGTTATCAGTGTAATGAAGCGCC-BHQ1 3’ 300 nM Wada et al., 2007 
RSV Probe 5’ FAM-CTTCACGAAGGCTCCACATACACAGCWG-BHQ1 3’ 300 nM Brittain-Long et al., 2008 
AdV Probe 5’ HEX-TGCACCAGACCCGGGCTCAGGTACTCCGA-BHQ1 3’ 300 nM Brittain-Long et al., 2008 
Mpneumo Probe 5’ FAM-TGGCCCAAGACCCCTCCAATCCTT-BHQ1  3’ 300 nM This study 
Lpneumo Probe 5’ HEX-CTCGCGTCACAATGCCACGGTGT- BHQ1 3’ 300 nM This study 
Cpneumo Probe 5’ HEX-ACATGCTCCACTGCTTGTGCGGGC-BHQ1 3’ 300 nM This study 
GAPDH (DNA) Probe 5’ FAM- TCAGCAATGCCTCCTGCACCACCA-BHQ1 3’ 300 nM This study 
 
dFAM: 6-carboxyfluorescein; HEX: hexachloro-6-carboxyfluoroscein; Cy5.5/Cy5: tetramethyl-indodicarbocyanine, BHQ1- Black hole quencher 
1; BHQ3- Black hole quencher 3; BBQ- BlackBerry quencher. 
 
 
2.5.3. Singleplex reactions 
Singleplex real-time PCR reactions were initially performed using SYBR Green I to establish the 
appropriate reaction conditions and to ascertain whether the primers were functional. TaqMan 
probes were subsequently individually tested to establish whether the probe was functioning 
correctly and that the reaction conditions were suitable.  
 
2.5.3.1.SYBR® Green I 
The SYBR Green I based real-time PCR assay does not require probes and is economical and 
easily adapted from conventional PCR. iQ™ SYBR Green Supermix (Bio-Rad, Hercules, USA) 
was used for SYBR Green I reactions. Melting curves were generated at the end of reactions 
involving SYBR Green I using the Chromo4 Opticon Monitor™ version 3.1 software to confirm 
the identity of the organism. However, melting temperatures may vary slightly as the SYBR 
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Green I concentration changes. Thermocycling conditions of organisms investigated are shown in 
the tables below. Some organisms shared the same cycling conditions and these were later 
grouped and multiplexed, as will be shown in the next section of this chapter. 
 
Table 2.3: Real-time PCR thermocycling conditions for FluA, FluB and hMPV. These reactions were 
initially done as separate single real-time PCR reactions using SYBR Green I, then using TaqMan probes 
and finally multiplexed.  
Step Temperature Time Number of Cycles 
Initial denaturation 95°C 3 minutes 1 
95°C 30 seconds 
55°C 30 seconds 
Denaturation 
Annealing 
Extension 72°C 30 seconds 
Plate Read  
49 
Melting Curve 55°C to 90°C 1 second 1 
 
Three-step real-time PCR reactions were performed for all bacteria and viruses investigated and 
thermocycling conditions using SYBR Green I were the same as those shown in Table 2.3 for all 
except for the annealing temperatures: PIV1 and PIV3 (49oC), EBV, CMV and GAPDH (RNA) 
(56oC), RSV, AdV and GAPDH (DNA) (58oC) and PIV2 (57oC). A two-step real-time PCR 
reaction was performed for P. jirovecii and thermocycling conditions are shown in Table 2.4. 
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Table 2.4: Real-time PCR thermocycling conditions for P. jirovecii. 
Step Temperature Time Number of Cycles 
Initial denaturation 95°C 3 minutes 1 
95°C 1 minute 
60°C 1 minute 
Denaturation 
Annealing + Extension 
Plate Read 
 
39 
Melting Curve 55°C to 90°C 1 second 1 
 
 
2.5.3.2.TaqMan probes 
 
After succeeding with the SYBR Green I real-time PCR reactions, reactions incorporating 
TaqMan probes were performed. Thermocycling conditions used were the same as those used in 
the SYBR Green I reactions but excluded the melting curve generation step. SYBR Green I only 
was used for PIV2, C. psittaci and P. jirovecii. These organisms were detected only with SYBR 
Green I since they could not be multiplexed and SYBR Green I is more economical than probes. 
 
All primers and probes were manufactured by Inqaba Biotech (Pretoria, South Africa) except for 
FluB, hMPV, PIV1 and PIV3 which were manufactured by TIB MolBiol (Berlin, Germany). 
Probes were labeled with the dyes FAM, HEX, CY5 and CY5.5 as they are distinguishable from 
each other due to their different wavelength maxima. Primers and probes were added to each 
PCR reaction at the concentrations shown (Tables 2.1 and 2.2). iQ™ Supermix (Bio-Rad, 
Hercules, USA) was the master mix used for TaqMan singleplex reactions and iQ™ Multiplex 
PowerMix (Bio-Rad, Hercules, USA) for TaqMan multiplex reactions. 
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2.5.4. Multiplex reactions 
Multiplex real-time PCR allows for the exponential amplification of nucleic acid with the use of 
more than one primer and probe set, thereby permitting the detection of several DNA, cDNA or 
plasmid targets in the same reaction vessel. All multiplex real-time PCR reactions were 
performed in total volumes of 50 µl in thin-walled 0.2 ml white PCR tube strips (Abgene, Surrey, 
UK) unless otherwise stated. Negative controls (no template) for each organism were included in 
each experiment. Primers and probes of the organisms multiplexed correspond to those described 
above (Tables 2.1 and 2.2). It was ensured that organisms to be multiplexed had probes labeled 
with different dyes to prevent overlap. Organisms were grouped to be multiplexed in the manner 
shown below from reaction 1 to reaction 6. Although many of the primers and probes have been 
published, in this study, they have been multiplexed in novel ways (Reaction 1, 2 and 4). In 
reaction 1, primer and probe sequences of Influenza virus A were adopted from Templeton et al., 
2004 and those of Influenza virus B and hMPV were from Gunson et al., 2005. In reaction 2, 
primer and probe sequences of PIV1 were adopted from Templeton et al., 2004 and those for 
PIV3 from Gunson et al., 2005. In reaction 4, both primer and probe sequences were adopted 
from Brittain-Long et al., 2008, but were not multiplexed as was done in this article. 
 
 Reaction 1: Influenza virus A, Influenza virus B and human Metapneumovirus  
The multiplex reaction was performed at final forward and reverse primer concentrations of 
1500nM (FluA), 500nM (FluB) and 750nM (hMPV). Probes were added to the reaction at the 
concentrations shown (Table 2.2). 
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 Reaction 2: Parainfluenza virus 1 and parainfluenza virus 3 
The multiplex reaction was performed using final forward and reverse primer concentrations 
of 1000nM (PIV1) and 500nM (PIV3). Probes were added to the reaction at the 
concentrations shown (Table 2.2). 
 
 Reaction 3: Epstein-Barr virus and cytomegalovirus 
The reaction was performed in a total volume of 25 µl. Primers and probes were added at the 
concentrations shown (Tables 2.1 and 2.2). 
 
 Reaction 4: Respiratory syncytial virus and adenovirus 
This multiplex reaction was performed at final primer concentrations of 1000nM (RSV) and 
500nM (AdV). Probes were added at the concentrations shown (Table 2.2). 
 
 Reaction 5: Mycoplasma pneumoniae and Legionella pneumophila 
The reaction was performed in a total volume of 25 µl. Primers and probes were added at the 
concentrations shown (Tables 2.1 and 2.2). 
 
 Reaction 6: Chlamydia pneumoniae and Glyceraldehyde-3-phosphate dehydrogenase 
(DNA) 
The reaction was performed in a total volume of 25 µl. Primers and probes were added to at 
the concentrations shown (Tables 2.1 and 2.2). 
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2.6.Interpretation of real-time PCR data  
 
A positive real-time PCR result was determined by identifying the threshold cycle number (Ct) at 
which standardized reporter dye emission raised above background noise (equivalent to the mean 
baseline emission plus 10X the standard deviation of the mean baseline fluorescence calculated 
for PCR cycles 3 – 15) (Mackay 2004) which was calculated by the Chromo4 Opticon Monitor 
3.1 software. Manual adjustment of the baseline was done in instances where fluorescence was 
low, or background noise was high. 
 
2.7.Agarose gel electrophoresis 
 
After real-time PCR on the Chromo4 thermocycler (Bio-Rad, Hercules, USA), amplification 
products were analysed by electrophoresis in 2% (w/v) (singleplex reactions) or 3% (w/v) 
(multiplex reactions) electroendosmotic (EEO) agarose in 1X Tris acetate EDTA (TAE) buffer. 
Six microliters of 50bp O'GeneRuler™ (Fermentas GMBH, Germany) was used as the marker. 
DNA was resolved at a constant voltage of 100 V. DNA bands were visualised and its image 
captured under UV light in the Gel doc 1000 image system (Bio-Rad, Hercules, USA).  
 
2.8.Seeplex detection kits 
The Seeplex® RV5 auto-capillary electrophoresis (ACE) Screening kit (Seegene, Seoul, Korea) 
was used to screen for viruses in nasopharyngeal swabs. Fifteen viral pathogens (FluA, FluB, 
hMPV, PIV1, PIV2, PIV3, rhinovirus A, rhinovirus B, coronavirus 229E, coronavirus NL63, 
coronavirus OC43, coronavirus HKU1 and bocavirus) can be detected by this kit, 6 of which can 
be detected by the real-time PCR assays used in this study. For bacterial detection, the Seeplex® 
Pneumobacter ACE detection kit (Seegene, Seoul, Korea) was used. The kit detects 6 pathogens 
(M. pneumoniae, L. pneumophila, S. pneumoniae, Haemophilus influenzae, Bordetella pertussis 
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and C. pneumoniae), 3 of which can be detected by the real-time PCR reactions developed in this 
study. Briefly, PCR was conducted in a final volume of 20 µl containing 4 µl of 5X RV5 ACE 
primer mix in the case of viral detection from nasopharyngeal swabs or 5X PB ACE primer mix 
in the case of bacterial detection from sputum samples, 3 µl of 8-MOP solution and 10 µl 2X 
Multiplex Master Mix and 3 µl of the sample nucleic acid. A positive and negative control 
supplied with the kits was included for all reactions performed. PCR was performed in an iCycler 
iQTM (Bio-Rad, Hercules, USA) with  the following thermal profile: An initial hot start step at 
94oC for 15min, 40 cycles at 94oC for 30 sec, 60oC for 1.5 min, 72oC for 1.5 min and 1 cycle for 
10 min at 72oC. Detection was performed on a 2% agarose gel stained with ethidium bromide 
(0.5µg/ml). DNA marker (5 µl) (PB ACE Marker or RV5 ACE Marker) supplied with the 
individual kits and 5µl of PCR product was loaded on the agarose gel. Six microlitres of a 50bp 
DNA ladder (Fermantas, O'GeneRuler™ #SM1138, Fermentas GMBH, Germany) was also 
loaded next to the kit DNA marker to compare band sizes. Gels images were captured using a Gel 
Doc 1000 image system (Bio-Rad, Hercules, USA). 
 
2.9.Cloning 
The viral culture supernatants, bacterial and fungal cultures that were used as positive controls 
(except L. pneumophila and hMPV) could not be quantitated so, as a result, plasmids containing 
target sequences were constructed. The targets of all studied organisms were cloned except for L. 
pneumophila which was available as a viable culture, and human metapneumovirus, which was 
available commercially as a plasmid (TIB MolBiol, Berlin, Germany). Bands in the gel were 
rapidly excised under UV illumination and purified using the QIAquick Gel Extraction Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The product was ligated to 
pGEM®-T Easy Vector System (Promega, Madison, WI) according to manufacturer’s 
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recommendations using T4 DNA ligase (Amersham Pharmacia Biotech, Little Chalfont, UK). 
This was transformed into Library Efficiency® DH5α  Competent Cells (Invitrogen, Carlsbad, 
USA) with the genotype F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1 λ-. Transformed cells were plated onto Luria-Bertani (LB)-agar 
supplemented with ampicillin (100µg/ml), 5-bromo-4-chloro-3-indole-β-D-galactopyranoside 
(X-gal), and Isopropyl-β−D-thiogalactopyranoside (IPTG) overnight at 37oC.  
 
To confirm the presence of the insert in white colonies, a crude nucleic acid extraction was 
performed on 3 colonies of each ligation. Briefly, sterile toothpicks were used to pick the 
colonies and transfer them to 200 µl sterile water in 1.5 ml tubes. The tubes were centrifuged at 
14 000 x g for 2 min before being placed in a boiling water bath for 5 min. The lysates were then 
centrifuged at 6 800 x g for 2 min to settle the debris and the supernatant containing the nucleic 
acid was then transferred to a new tube. A real-time PCR using specific primers was performed 
to ensure the presence of the insert. Minipreps of recombinant pGEM-T plasmids were prepared 
from viral, fungal and bacterial cultures using Qiagen-tip 20 columns (Qiagen, Hilden, Germany) 
following the QIAGEN plasmid Mini Kit protocol.  Briefly, a freshly streaked transformed 
colony was picked from LB-agar supplemented with ampicillin (100µg/ml) and inoculated into 5 
ml LB broth containing 5 µl ampicillin (100µg/ml) for 8 hrs at 37oC shaking at 300 rpm. This 
starter culture was then diluted by transferring 6µl into 3 ml of LB broth supplemented with 3 µl 
ampicillin (100µg/ml). The culture was left to shake at 37oC for 12-16 hrs at approximately 300 
rpm. The cell cultures were harvested by centrifugation at 6000 x g for 15 min and the pellet 
resuspended in 0.3 ml of Buffer P1 with RNase A and LyseBlue reagent added to it. Buffer P2 
(0.3 ml) was added to the mixture and the tube inverted 4-6 times. The mixture immediately 
turned blue upon adding Buffer 2 and this was incubated at room temperature for 5 min. Chilled 
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Buffer P3 (0.3 ml) was added to the blue solution and mixed thoroughly by vigorously inverting 
the tube 4-6 times before incubating on ice for 5 min. A fluffy white material immediately 
formed in the tube on addition of Buffer P3. All traces of blue disappeared on mixing and a 
homogenous colorless suspension was formed indicating effective precipitation of SDS. 
Centrifugation was performed at 14 000 x g and the clear supernatant was promptly transferred to 
the QIAGEN-tip 20 column which had been calibrated with 1ml of Buffer QBT and allowed to 
enter the resin by gravity flow. The column was then washed twice with 2 ml Buffer QC before 
eluting plasmid with 0.8 ml Buffer QF into a clean 1.5 ml tube. Isopropanol (0.56 ml) was added 
to the eluted DNA, mixed and centrifuged at 14 000 x g for 30 min to precipitate it. The 
supernatant was decanted carefully making sure not to disturb the pellet. One milliliter of ethanol 
(70%) was used to wash the pellet by centrifuging at 14 000 x g for 10 min. The supernatant was 
decanted and the pellet was air-dried for 5-10 min before redissolving the plasmid in TE buffer 
(pH 8.0). 
 
The presence of the correct insert was confirmed by sequencing using the plasmid M13 forward 
primer (5'-GTAAAACGACGGCCAGT-3') manufactured by Inqaba Biotech (South Africa). The 
sequencing reactions were cycled for 25 cycles using the following conditions: 95oC for 30 sec, 
50oC for 30 sec and 60oC for 4 min on the iCycler iQTM (Bio-Rad, Hercules, USA). Separation of 
the labeled fragments was done by Inqaba Biotech and results were analysed using Ridom Trace 
Edit and Ridom Q Align software (Ridom, Würzburg, Germany). Presence of the conserved 
regions within the plasmids was identified using the BLAST program on PubMed 
(www.ncbi.nlm.nih.gov/blast). 
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2.10. Glycerol stock preparation 
One of the colonies of each organism containing the insert was plated out on LB-agar 
supplemented with ampicillin (100µg/ml) and incubated at 37oC overnight. A single colony of 
the clone was picked off of the plate and inoculated in a McCartney bottle containing 3 ml LB 
broth with 3 µl ampicillin (100µg/ml). The bottles were incubated in an incubator-shaker (New 
Brunswick Scientific, Series 25, New Brunswick, NJ) at 37oC shaking at 225 rpm for 8 hrs. The 
culture was transferred to 1.5 ml tubes and centrifuged at maximum speed for 2 min (Eppendorf 
centrifuge 5417C, Eppendorf, UK). The supernatant was removed and the pellet resuspended in a 
1:1 ratio of 30% sterile glycerol (SMM Chemicals, Booysens, South Africa) and water by 
vortexing. The glycerol stocks were stored at -70oC. 
 
2.11. Sensitivity assays 
The plasmid concentration of each of the organisms cloned was measured using the NanoDrop 
ND-100 spectrophotometer (NanoDrop Technologies, Wilmington, DE) at 260 nm. Serial 
dilutions using sterile water were thereafter performed (1 to 100 000 copies/µl). The sensitivity of 
the real-time PCR assays was tested on the 3 lowest dilutions (1 to 100 copies/µl) of the target 
gene plasmid construct as the template. Multiplex assays were tested for their ability to co-
amplify multiple gene targets present at the lowest concentrations detectable by the singleplex 
assays. 
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CHAPTER 3A: REAL-TIME PCR ASSAYS (POSITIVE CONTROLS) 
 
 
 
Real-time PCR assays were initially optimized in singleplex using SYBR ® Green I (Figures 3.1-
3.17) and then TaqMan probes (Figures 3.18-3.30) before multiplex reactions (Figures 3.31a-
3.36c) were performed. Appropriate primer combinations that could allow multiplexing of M. 
pneumoniae, C. pneumoniae, C. psittaci, L. pneumophila and GAPDH could not be obtained 
from the literature and as a result, they were designed using the Beacon Designer Software 
Program (Biosoft International). In instances where no suitable multiplex partner was found, or 
where limitations on the synthesis of appropriately labelled probes were encountered, the 
reactions were performed using SYBR Green I in singleplex. 
 
3.1.Singleplex reactions 
3.1.1. SYBR® Green I 
Initially performing the reactions with SYBR Green I helped to establish the appropriate reaction 
conditions and to ascertain that the primers were working correctly. For the majority of reactions 
performed (FluA, FluB, hMPV, RSV, PIV1, PIV2, PIV3, L. pneumophila, M. pneumoniae and 
GAPDH (DNA)), two or more different sets of primers had to be tested before a positive real-
time PCR result was obtained and the reactions multiplexed successfully. All SYBR Green I PCR 
end products were separated on 2% agarose gels (see appendix B). 
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a. Influenza A virus  
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
 
 
Figure 3.1: Melting curve analysis of FluA generated when using SYBR Green I. The signature melting 
temperature of FluA (81oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 
 
 
b. Influenza B virus  
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Figure 3.2: Melting curve analysis of FluB generated when using SYBR Green I. The signature melting 
temperature of FluB (83oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 
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c. Human metapneumovirus  
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Figure 3.3: Melting curve analysis of hMPV generated when using SYBR Green I. The signature melting 
temperature of hMPV (80oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 
 
d. Parainfluenza virus 1  
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Figure 3.4: Melting curve analysis of PIV1 generated when using SYBR Green I. The signature melting 
temperature of PIV1 (80oC) is indicated by the sharp tall red peak corresponding to the positive control. The 
smaller red peak indicates a primer-dimer (75oC) as judged by gel electrophoresis (Figure B3A). 
Temperature is plotted versus fluorescence signal. 
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e. Parainfluenza virus 2  

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
Figure 3.5: Melting curve analysis of PIV2 generated when using SYBR Green I. The signature melting 
temperature of PIV2 (78oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 

f. Parainfluenza virus 3  

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Figure 3.6: Melting curve analysis of PIV3 generated when using SYBR Green I. The signature melting 
temperature of PIV3 (78oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 
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g. Adenovirus 

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
Figure 3.7: Melting curve analysis of AdV generated when using SYBR Green I. The signature melting 
temperature of AdV (88oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 

h. Respiratory syncytial virus  
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Figure 3.8: Melting curve analysis of RSV generated when using SYBR Green I. The signature melting 
temperature of RSV (80oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 
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i. Cytomegalovirus  
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Figure 3.9: Melting curve analysis of CMV generated when using SYBR Green I. The signature melting 
temperature of CMV (85oC) is indicated by the sharp red peak corresponding to the positive control. The 
green peak indicated a primer-dimer (78oC) as judged by gel electrophoresis (Figure B1A). Temperature is 
plotted versus fluorescence signal. 

j. Epstein-Barr virus  
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Figure 3.10: Melting curve analysis of EBV generated when using SYBR Green I. The signature melting 
temperature of EBV (82oC) is indicated by the sharp red peak corresponding to the positive control. 
Temperature is plotted versus fluorescence signal. 
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k. M. pneumoniae  
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Figure 3.11: Melting curve analysis of M. pneumoniae generated when using SYBR Green I. The signature 
melting temperature of M. pneumoniae (86oC) is indicated by the sharp red peak corresponding to the 
positive control. Temperature is plotted versus fluorescence signal. 
 
l. L. pneumophila 
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Figure 3.12: Melting curve analysis of L. pneumophila generated when using SYBR Green I. The signature 
melting temperature of L. pneumophila (82oC) is indicated by the sharp red peak corresponding to the 
positive control. The green peak indicates the formation of non-specific PCR product (87oC) as judged by 
gel electrophoresis (Figure B9A). Temperature is plotted versus fluorescence signal. 
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m. C. pneumoniae  

	

 
 
Figure 3.13: Melting curve analysis of C. pneumoniae generated when using SYBR Green I. The signature 
melting temperature of C. pneumoniae (84oC) is indicated by the sharp red peak corresponding to the 
positive control. Temperature is plotted versus fluorescence signal. 
 
n. GAPDH (DNA) 
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Figure 3.14: Melting curve analysis of GAPDH (DNA) generated when using SYBR Green I. The signature 
melting temperature of GAPDH (DNA) (84oC) is indicated by the sharp red peak corresponding to the 
positive control. Temperature is plotted versus fluorescence signal. 
  - . /-   0
 
 	
 
 1 
+	 	
 
 	
 
 1 
Chapter 3A: Results - Real-time PCR assays (positive controls) 
 70
o. GAPDH (RNA) 
 
	

 
 
Figure 3.15: Melting curve analysis of GAPDH (RNA) generated when using SYBR Green I. The signature 
melting temperature of GAPDH (RNA) (85oC) is indicated by the sharp red peak corresponding to the 
positive control. Temperature is plotted versus fluorescence signal. 
 
p. P. jirovecii 
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Figure 3.16: Melting curve analysis of P. jirovecii generated when using SYBR Green I. The signature 
melting temperature of P. jirovecii (77oC) is indicated by the sharp red peak corresponding to the positive 
control. Temperature is plotted versus fluorescence signal. 
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q. C. psittaci  
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Figure 3.17: Melting curve analysis of C. psittaci generated when using SYBR Green I. The signature 
melting temperature of C. psittaci (81oC) is indicated by the sharp red peak corresponding to the positive 
control. Temperature is plotted versus fluorescence signal. 
 
 
3.1.2 TaqMan probes 

Once primers and reactions conditions were found to work with SYBR Green I, TaqMan probes 
were used. In all real-time PCR reactions performed, the variation in fluorescence levels of the 
TaqMan probes was considerable and dye-dependent. Reactions involving probes possessing the 
FAM, CY5 and CY5.5 dyes displayed a higher maximum fluorescence level in the order of 0.11 
to 0.62 than those possessing the HEX dye which were in the order of 0.006 to 0.55. Some of the 
graphs generated using TaqMan probes (hMPV, PIV1, PIV3 and CMV) did not display a typical 
exponential real-time PCR fluorescence curves and this is believed to be due to the degradation 
of the probes after storage. All real-time PCR end products of TaqMan probe reactions were 
separated on 2% agarose gels (see appendix B). 
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a. Influenza A virus  
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Figure 3.18: Real-time PCR singleplex analysis of FluA using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
 
b. Influenza B virus  

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Figure 3.19: Real-time PCR singleplex analysis of FluB using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 

 
 	
 
 
 
 	
 
Chapter 3A: Results - Real-time PCR assays (positive controls) 
 73
c. Human metapneumovirus  
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Figure 3.20: Real-time PCR singleplex analysis of hMPV using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
 
d. Parainfluenza virus 1 
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Figure 3.21: Real-time PCR singleplex analysis of PIV1 using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
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e. Parainfluenza virus 3  
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Figure 3.22: Real-time PCR singleplex analysis of PIV3 using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
 
Adenovirus 
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Figure 3.23: Real-time PCR singleplex analysis of AdV using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
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Respiratory syncytial virus  
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Figure 3.24: Real-time PCR singleplex analysis of RSV using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
 
f. Cytomegalovirus 

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Figure 3.25: Real-time PCR singleplex analysis of CMV using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
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Epstein-Barr virus  
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Figure 3.26 Real-time PCR singleplex analysis of EBV using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 

g. M. pneumoniae  

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Figure 3.27: Real-time PCR singleplex analysis of M. pneumoniae using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
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h. L. pneumophila  
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Figure 3.28: Real-time PCR singleplex analysis of L. pneumophila using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
 
i. C. pneumoniae 
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Figure 3.29: Real-time PCR singleplex analysis of C. pneumoniae using a TaqMan probe. Plot of change in 
fluorescence signal versus cycle number is shown. 
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j. GAPDH (DNA) 
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Figure 3.30: Real-time PCR singleplex analysis of GAPDH (DNA) using a TaqMan probe. Plot of change 
in fluorescence signal versus cycle number is shown. 
 
 
 
3.2.Multiplex reactions 
 
To reduce the number of total reactions performed using TaqMan probes, the reactions were 
multiplexed. Below is shown individual traces of fluorescence graphs of each organism as 
multiplexed. The multiplex reactions were grouped as follows: PIV1 and PIV3; RSV and AdV; 
EBV and CMV, M. pneumoniae and L. pneumophila; GAPDH and C. pneumoniae; and lastly, 
FluA, FluB and hMPV. The multiplex real-time PCR end products were separated on a 3% 
agarose gel to confirm that products of the expected sizes were produced (see Appendix C). The 
presence of several pairs of primers and probes in a single reaction tube increases the 
probabilities of obtaining non-specific amplification products, and in particular, the formation of 
primer-dimers was observed in the agarose gels (Appendix C). We noted that M. pneumoniae and 
L. pneumophila amplicons were too similar in size to be distinguished accurately on an agarose 
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gel (102 and 107bp respectively) (Figure C5A). However, it was evident from the real-time PCR 
fluorescence graphs, that product had been formed (Figures 3.34a and b). 
 
a. Parainfluenza virus 1 and Parainfluenza virus 3  

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Figure 3.31a: Real-time PCR analysis of PIV1 in a multiplex reaction using a TaqMan probe. Plot of change 
in fluorescence signal versus cycle number is shown. 
 
 &
 
 
Figure 3.31b: Real-time PCR analysis of PIV3 in a multiplex reaction using a TaqMan probe. Plot of 
change in fluorescence signal versus cycle number is shown. 
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b. Respiratory syncytial virusandAdenovirus 
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Figure 3.32a: Real-time PCR analysis of RSV in a multiplex reaction using a TaqMan probe. Plot of change 
in fluorescence signal versus cycle number is shown. 
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Figure 3.32b: Real-time PCR analysis of AdV in a multiplex reaction using a TaqMan probe. Plot of change 
in fluorescence signal versus cycle number is shown. 
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c. Cytomegalovirus and Epstein-Barr virus  

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Figure 3.33a: Real-time PCR analysis of EBV in a multiplex reaction using a TaqMan probe. Plot of change 
in fluorescence signal versus cycle number is shown. 
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Figure 3.33b: Real-time PCR analysis of CMV in a multiplex reaction using a TaqMan probe. Plot of 
change in fluorescence signal versus cycle number is shown. 
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d. M. pneumoniae and L. pneumophila  
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Figure 3.34a: Real-time PCR analysis of M. pneumoniae in a multiplex reaction using a TaqMan probe. Plot 
of change in fluorescence signal versus cycle number is shown. 
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Figure 3.34b: Real-time PCR analysis of L. pneumophila in a multiplex reaction using a TaqMan probe. 
Plot of change in fluorescence signal versus cycle number is shown. 
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e. GAPDH (DNA) and C. pneumoniae  
 
 $ 
 
 
Figure 3.35a Real-time PCR analysis of GAPDH (DNA) in a multiplex reaction using a TaqMan probe. Plot 
of change in fluorescence signal versus cycle number is shown. 

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Figure 3.35b: Real-time PCR analysis of C. pneumoniae in a multiplex reaction using a TaqMan probe. Plot 
of change in fluorescence signal versus cycle number is shown. 
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f. Influenza A virus Influenza B virus and human metapneumovirus  
 
 $ 
 
 
Figure 3.36a: Real-time PCR analysis of FluA in a multiplex reaction using a TaqMan probe. Plot of change 
in fluorescence signal versus cycle number is shown. 
 
. )3 
 
 
Figure 3.36b: Real-time PCR analysis of FluB in a multiplex reaction using a TaqMan probe. Plot of change 
in fluorescence signal versus cycle number is shown. 
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Figure 3.36c: Real-time PCR analysis of hMPV in a multiplex reaction using a TaqMan probe. Plot of 
change in fluorescence signal versus cycle number is shown. 
 
3.3.Efficiency of reactions 
Generally, the efficiency of a real-time reaction can be calculated using data from the 
fluorescence curve using the following formula: Efficiency = 10 (-1/slope) (Wong and Medrano, 
2005). A steep slope (value = 2) indicates doubling of amplicons thus optimal PCR efficiency. In 
this project, it was observed that, according to calculations performed by the Opticon Monitor™ 
version 3.1 software of the Chromo4 system, real-time PCR reaction efficiencies of the SYBR 
Green I reactions were higher than those of TaqMan singleplex probe assays (Figure 3.37). This 
can be attributed to the use of different reaction mastermixes, the non-specificity of SYBR Green 
I which results in the formation of primer-dimer artifacts and non-specific products contributing 
to the increase in double-stranded molecules detected and more generally, the different 
chemistries involved. 
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The majority of probe reactions had a PCR efficiency of less than 1.4 and this is believed to be 
due to probe degradation over time as the TaqMan probes were used later in the project. 
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Figure 3.37: Bar chart illustrating the difference in amplification efficiencies between TaqMan probes and SYBR 
Green I for each organism. The Opticon Monitor™ version 3.1 software of the Chromo4 real-time PCR machine was 
used to calculate the values. 
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CHAPTER 3B: RESULTS - CLONING 
 
 
 
3.4.Cloning 
 
With the exception of L. pneumophila and hMPV, the positive controls obtained contained an 
unknown copy number. It was therefore necessary to generate positive control plasmids to use 
for sensitivity assays. After obtaining positive results for the real-time PCR assays performed 
on the controls, the product was cloned. After transformation, real-time PCR was performed on 
the white colonies (Figure 3.38) to confirm the presence of the insert. Confirmed clones were 
purified and the plasmid separated on a 2% agarose gel. All colonies picked presumptively 
contained inserts as judged by agarose gel electrophoresis. This was confirmed by organism 
specific PCR and sequencing of the plasmid inserts for all relevant organisms. 
 
Figure 3.38: Blue-white screening of transformed cells plated out on LB agar supplemented with ampicillin,  
X-gal and IPTG. The white colonies contain the insert and the majority of the blue colonies do not. 
Blue colony 
White colony 
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CHAPTER 3C: RESULTS - SENSITIVITY ASSAYS  
 
 
 
Despite the fact that the assays used in this study were qualitative, it is of value to know the 
detection limits of the reactions used to enable their application in a clinical setting. Serial 
dilutions of recombinant plasmids were performed (10000 copies/µl to 1 copy/µl) using milliQ 
water. Real-time PCR reactions were performed in both singleplex and multiplex, on the 3 lowest 
copy numbers (1, 10 and 100 copies/µl) to determine the detection limit of the assays.  
 
3.5.Singleplex reactions 
 
Detection limits of the real-time PCR assays were determined using TaqMan probes for all 
reactions that could be multiplexed (Figures 3.39-3.51) and SYBR Green I for those that were not 
(PIV2, C. psittaci and P. jirovecii) (Figures 3.52-3.54). All real-time PCR end products of 
singleplex sensitivity assays were run on 2% agarose gels (see appendix B). Amplification 
products were visible on the agarose gel indicating decreasing band intensity with increasing 
dilutions. No amplicons were detected for the negative controls. The lower limits of detection for 
the majority of the assays were 1 copy/µl of plasmid with CMV and L. pneumophila assays 
detected at 10 copies/µl and 10 CFUs/µl respectively.  
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3.5.1. TaqMan Probes 
 
a. Influenza A virus  
 

 
 
Figure 3.39: Fluorescence graph of FluA plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
b. Influenza B virus  
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Figure 3.40: Fluorescence graph of FluB plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
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c. Human metapneumovirus  
 
 !"#"

 
Figure 3.41: Fluorescence graph of hMPV plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
d. Parainfluenza virus 1  
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Figure 3.42: Fluorescence graph of PIV1 plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
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e. Parainfluenza virus 3  

 !"
 
 
Figure 3.43: Fluorescence graph of PIV3 plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
f. Adenovirus 

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Figure 3.44: Fluorescence graph of AdV plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
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g. Respiratory syncytial virus  

 
 

Figure 3.45: Fluorescence graph of RSV plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
h. Cytomegalovirus  

  
 
 
Figure 3.46: Fluorescence graph of CMV plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
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i. Epstein-Barr virus  
 

 
 
Figure 3.47: Fluorescence graph of EBV plasmid serial dilutions demonstrating the sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
j. M. pneumoniae  


 
Figure 3.48: Fluorescence graph of M. pneumoniae plasmid serial dilutions demonstrating the sensitivity of 
the TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
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k. L. pneumophila  

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Figure 3.49: Fluorescence graph of L. pneumophila plasmid serial dilutions demonstrating the sensitivity of 
the TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
l. C. pneumoniae  

  
 
Figure 3.50: Fluorescence graph of C. pneumoniae plasmid serial dilutions demonstrating the sensitivity of 
the TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
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m. GAPDH (DNA) 


 
 
Figure 3.51: Fluorescence graph of GAPDH (DNA) plasmid serial dilutions demonstrating the sensitivity of 
the TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
3.5.2 SYBR® Green I 
a. P. jirovecii  
 
* !) - 		'
 
 
Figure 3.52: Melting curve analysis of P. jirovecii plasmid serial dilutions demonstrating the sensitivity of 
the SYBR Green I assay. The signature melting temperature of P. jirovecii (77oC) is indicated by the sharp 
red, green and blue peaks. Temperature is plotted versus fluorescence signal. 
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b. C. psittaci  
 
* !) - 		'


Figure 3.53: Melting curve analysis of C. psittaci plasmid serial dilutions demonstrating the sensitivity of 
the SYBR Green I assay. The signature melting temperature of C. psittaci (81oC) is indicated by the sharp 
red, green and blue peaks. Temperature is plotted versus fluorescence signal. 
 
c. Parainfluenza virus 2 
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
Figure 3.54: Melting curve analysis of PIV2 plasmid serial dilutions demonstrating the sensitivity of the 
SYBR Green I assay. The signature melting temperature of PIV2 (78oC) is indicated by the sharp red, green 
and blue peaks. Temperature is plotted versus fluorescence signal. 
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3.6.Multiplex reactions 
 
To determine whether the presence of multiple organisms or targets could potentially reduce 
multiplex sensitivity, lowest dilutions of each target were tested. For L. pneumophila and CMV, 
the lowest concentration detected in their singleplex sensitivity reactions was 10 CFU/µl and 10 
copies/µl respectively and these were the dilutions used for the multiplex reactions. Below is 
shown individual traces of fluorescence graphs of each organism multiplexed (Figures 3.55a-
3.60c). The real-time PCR end products for multiplex reactions were separated on a 3% agarose 
gel to confirm that products of the expected sizes were produced (see Appendix C). Despite the 
anomalous fluorescence curve produced for PIV1 in the multiplex reaction (Figure 3.59a), 
amplicon separation on 3% agarose gel (Figure C4B) indicated that the desired amplicon was 
produced. 
 
a. Respiratory syncytial virus and Adenovirus  
  

 
 
Figure 3.55a: Fluorescence graph of RSV multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
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Figure 3.55b: Fluorescence graph of AdV multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
 
 
b. Epstein-Barr virus and Cytomegalovirus  
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Figure 3.56a: Fluorescence graph of EBV multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
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  
 
 
Figure 3.56b: Fluorescence graph of CMV multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
 
c. GAPDH (DNA) and C. pneumoniae  
 
 
 
 
 
Figure 3.57a: Fluorescence graph of GAPDH (DNA) multiplex reaction indicating sensitivity of the 
TaqMan assay. Change in fluorescence signal is plotted versus cycle number. 
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Figure 3.57b: Fluorescence graph of C. pneumoniae multiplex reaction indicating sensitivity of the TaqMan 
assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
d. M. pneumoniae and L. pneumophila  
 

 
 
Figure 3.58a: Fluorescence graph of M. pneumoniae multiplex reaction indicating sensitivity of the TaqMan 
assay. Change in fluorescence signal is plotted versus cycle number. 
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Figure 3.58b: Fluorescence graph of L. pneumophila multiplex reaction indicating sensitivity of the TaqMan 
assay. Change in fluorescence signal is plotted versus cycle number. 
 
 
e. Parainfluenza virus 1 and Parainfluenza virus 3  
 

 
 
Figure 3.59a: Fluorescence graph of PIV1 multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
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Figure 3.59b: Fluorescence graph of PIV3 multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
 
 
f. Influenza virus A Influenza virus B and human metapneumovirus  
 

 
 
Figure 3.60a: Fluorescence graph of FluA multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
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Figure 3.60b: Fluorescence graph of FluB multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
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Figure 3.60c: Fluorescence graph of hMPV multiplex reaction indicating sensitivity of the TaqMan assay. 
Change in fluorescence signal is plotted versus cycle number. 
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3.7. Summary of sensitivities of real-time PCR assays 
 
All the assays except those of CMV and L. pneumophila were able to detect the lowest copy 
number of 1 copy/µl. 

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CHAPTER 3D: RESULTS - PATIENT SAMPLES AND SIMULATIONS  
 
 

The 3 patients enrolled in this study were too few to be a representative of the incidence of CAP 
locally. However, we still proceeded to use these samples to test both real-time PCR assays as 
well as the Seeplex detection kits. The detection limits of Seeplex kits are reported by the 
manufacturer as 10 copies/3µl (3.3 copies/µl). The specificity of the Seeplex® RV5 ACE 
Screening kit and the Seeplex® Pneumobacter ACE Detection kit was validated with 26 and 23 
different respiratory viruses and bacteria respectively by the manufacturer.  
 
Nasopharyngeal swabs and sputum samples were collected from each of the CAP patients 
enrolled. The simulation of sample collection was performed in duplicate for nasopharyngeal 
swabs and on 2 different cystic fibrosis patient sputum samples. The duplicates were named 
simulation 1 and 2. Each of the nasopharyngeal simulation swabs was dipped into a viral culture 
mixture containing an equal volume of FluA, PIV1, PIV2, RSV and CMV. Other viruses were 
not included in sample simulation because they were either supplied in the form of RNA or 
cDNA or no viral culture remained. 
 
Each Seeplex detection kit was supplied with a size marker which displays all the bands 
corresponding to the amplicons that the kit can detect, including the internal control band. If a 
specimen showed the same sized fragment as any of the bands displayed by the marker bands, it 
was considered positive for that organism.  
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3.8.Pathogen detection using Seeplex kits 
3.8.1. Seeplex® Pneumobacter ACE detection kit 
The Pneumobacter ACE detection kit is designed to detect the internal control (900bp), M. 
pneumoniae (583bp), L. pneumophila (472bp), S. pneumoniae (350bp), H. influenzae (257bp), B. 
pertussis (200bp), and C. pneumoniae (146bp). This kit was used to test sputum samples for 
respiratory pathogens. An internal control in the form of a DNA plasmid is included in the 
Pneumobacter ACE Detection kit to identify specimens that contain substances that may interfere 
with the PCR reaction and to guarantee equivalent amplification of this internal control and the 
target DNA organisms. The internal control was co-amplified with target DNA from each sample 
tested. The internal control band was however absent for patient 3 in lane 7 of the gel shown in 
figure 3.61. Possible reasons for this may have been the presence of high pathogen load and 
depletion of reagents for the control reaction. A positive and negative control was included in the 
reaction performed and the 50bp DNA Ladder (Fermentas GMBH, Germany) was used alongside 
the PB ACE Marker supplied with the kit to ascertain band sizes produced.  
 
All the pathogens used to spike the simulated patient samples that were in the detection panel of 
the kits were detected. The simulated samples 1 and 2 were spiked with C. pneumoniae, C. 
psittaci and a single colony of L. pneumophila. These were the only samples that tested positive 
for L. pneumophila (lanes 3 and 4). All CAP patient samples as well as simulated sputum 
samples from cystic fibrosis patients tested positive for S. pneumoniae and H. influenzae. The 
simulated sputum samples were not spiked with either of these bacteria suggesting that the cystic 
fibrosis patients from whom the sputa were obtained were colonised with them. CAP patient 2 
(lane 6) appears not to be infected with C. pneumoniae whilst the other 2 CAP patients are. 
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
Sputum Samples Spiked organisms Detected organisms 
Simulation 1 L. pneumophila, C. pneumoniae, C. psittaci 
L. pneumophila, C. pneumoniae, S. pneumoniae, 
H. influenzae 
Simulation 2 L. pneumophila, C. pneumoniae, C. psittaci 
L. pneumophila, C. pneumoniae, S. pneumoniae, 
H. influenzae 
Patient 1 N/A C. pneumoniae, S. pneumoniae, H. influenzae 
Patient 2 N/A S. pneumoniae, H. influenzae 
Patient 3 N/A C. pneumoniae, S. pneumoniae, H. influenzae  
 
Figure 3.61: PCR results obtained using the Seeplex® Pneumobacter ACE detection kit. Amplicons of sputum 
samples from CAP patients (lanes 5-7) and simulated sputum samples obtained from cystic fibrosis patients (lane 3 
and 4) and spiked with CAP causing pathogens were separated on a 2% agarose gel stained with ethidium bromide. 
 
3.8.2. Seeplex® RV5 ACE detection kit 
The RV5 ACE detection kit is specifically designed to detect the internal control (1000bp), 
Influenza A virus (FluA) (206bp), Influenza B virus (FluB) (709bp), human respiratory syncytial 
virus (RSV) A or B (273bp), Others 1 (Human adenovirus (AdV), human parainfluenza virus 
(PIV) 1, 2, and 3, human bocavirus (BoV)) (534bp), Others 2 (human metapneumovirus (hMPV), 
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human coronavirus (CoV) 229E, NL63, OC43 and HKU1, human rhinovirus (hRV) A and B) 
(394bp). This kit was used to test nasopharyngeal swabs. The 50bp O’GeneRuler (Fermentas 
GMBH, Germany) was used in addition to the RV5 ACE Marker that was supplied with the kit to 
confirm the sizes of the bands produced. The internal control included in the kit was in the form 
of a DNA plasmid and was used to identify any contaminating substances interfering with the 
PCR reaction.  
 
All the pathogens used to spike the simulated patient samples that were in the detection panel of 
the kit were identified. Simulated swabs 1 and 2 (lanes 3 and 4) were spiked with viral culture 
supernatants of RSV, FluA, PIV1, PIV2 and CMV and tested positive for RSV A or B, FluA and 
“Others 1” which was either AdV, PIV 1, 2, 3 or BoV (Figure 3.62). The band corresponding to 
“Others 1” (534bp) in simulation 2 (lane 4) was however very faint. CMV detection is not within 
the scope of the kit thus its presence could not be confirmed using the kit. Patient 1 (lane 5) tested 
positive for “Others 2” which was hMPV, hRV or CoV. Patients 2 and 3 tested negative for all 
viruses within the detection panel of the kit. The internal control was co-amplified with target 
DNA from each sample tested. 
 
 
 
 

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
Swab Samples Spiked organisms Detected organisms 
Simulation 1 FluA, PIV1, PIV2, CMV, RSV FluA, RSV, Others 1 
Simulation 2 FluA, PIV1, PIV2, CMV, RSV FluA, RSV, Others 1 
Patient 1 N/A Others 2 
Patient 2 N/A a-------- 
Patient 3 N/A -------- 
  
a
-----: No organism detected 
Figure 3.62: PCR results obtained using the Seeplex® RV5 ACE detection kit. Amplicons from nasopharyngeal 
swabs obtained from CAP patients (lanes 5-7) and simulated nasopharyngeal swabs spiked with CAP causing 
pathogens (lanes 3 and 4) were separated on a 2% agarose gel stained with ethidium bromide.








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3.9.Pathogen detection using real-time PCR assays 
Real-time PCR was used to confirm the presence of spiked organisms, to compare the results 
with the Seeplex® Pneumobacter and RV5 detection kits, as well as to detect other organisms 
which were not within the detection panel of the Seeplex kits. 
 
3.9.1. Pathogen detection in simulated samples 
Only real-time PCR reactions to detect organisms used to spike the sputum samples and 
nasopharyngeal swabs were performed. All organisms used to spike the sputa and swabs were 
detected in the real-time PCR assays (see appendix E). Real-time PCR reactions were performed 
in duplicate on nasopharyngeal swabs and on two different sputum samples collected from cystic 
fibrosis patients. No large difference in Ct values was observed between any two duplicate 
samples for each organism tested, showing the reproducibility of the assays (Figures 3.63 and 
3.64).  
 
3.9.1.1.Singleplex reactions 
Singleplex reactions were performed using SYBR Green I for C. psittaci and PIV2 and TaqMan 
probes were used for L. pneumophila, C. pneumoniae, GAPDH (DNA), RSV, PIV1, FluA and 
CMV. Viruses were tested for in simulated nasopharyngeal swabs and bacteria in simulated 
sputum samples. GAPDH (RNA) was not tested for in simulated nasopharyngeal swabs because 
these swabs were not obtained from human subjects thus did not contain human cells. GAPDH 
(DNA) was co-extracted and co-amplified with the spiked bacteria to detect any inhibition 
present. All real-time PCR end products of singleplex assays were run on 2% agarose gels (see 
appendix D). No amplicons were detected for the negative controls. 
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All the viruses used to spike the swabs were detected by real time PCR and the Ct values 
obtained for the duplicates were in the range of 0.41 (1.53%) and 4.66 (19%) Ct. (Figure 3.63)  
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Figure 3.63: Analysis of real-time PCR results obtained from nasopharyngeal swabs spiked with different viral 
cultures simulating multiple viral infections in a patient  
 
Larger differences in Ct were observed with PIV2 and CMV (11% and 19% respectively) as 
calculated using the equation: 1 2
1 2
100
2( ) /
t t
t t
X
C C
C C
−
+
. The Ct values in simulation 1 for both these 
organisms were higher. This may have been due to pipetting errors.  
 
All the bacteria used to spike the sputum samples as well as the GAPDH (DNA) internal control 
were detected by real-time PCR. The range in Ct values of the bacteria in the spiked sputum 
duplicate samples was from 0.11 (0.004%) to 1.48 (5.7%) Ct (Figure 3.64). This was an 
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indication of the good reproducibility of the assays performed as no large differences were 
observed. 
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Figure 3.64: Analysis of real-time PCR results obtained from cystic fibrosis patient sputum samples spiked with 
bacterial cultures of C. pneumoniae and C. psittaci and a colony of L. pneumophila simulating multiple bacterial 
infections in a patient  
 
The internal control was successfully co-extracted and co-amplified in the reaction resulting in a 
fixed cycle threshold value. This indicated that DNA extraction was performed adequately 
without any major interference from inhibitory substances. The difference in GAPDH (DNA) Ct 
values between simulation 1 and 2 (3.46 Ct) was however higher than the Ct values observed for 
the bacteria investigated (Figure 3.64). This was to be expected, as the sputum samples would 
have contained different amounts of epithelial cells.  
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3.9.1.2.Multiplex reactions 
Of all the organisms available to spike sputum and nasopharyngeal swabs for the simulation of 
patient samples, the only multiplex reaction that could be performed was that of GAPDH (DNA) 
and C. pneumoniae. Real-time PCR end products of the multiplex assay were run on a 3% 
agarose gel (see appendix D). No amplicons were detected for the negative controls. 
 
3.9.2. Pathogen detection in CAP patient samples 
Real-time PCR was used to confirm the presence of organisms detected by the Seeplex 
Pneumobacter and RV5 detection kits as well as to detect other organisms which were not within 
the detection panel of the Seeplex detection kits. GAPDH (DNA) and GAPDH (RNA) were used 
as internal controls for real-time PCR reactions involving DNA and RNA organisms respectively. 
Real-time PCR reactions were performed in singleplex using SYBR Green I for those organisms 
that could not be multiplexed and an allowance of 1oC was given on the melting temperature of 
real-time PCR product produced to conclude that it was the desired amplicon since melting 
temperature can be affected by SYBR Green I concentrations (Giglio et al., 2003). This would 
allow for any pipetting errors. GAPDH (DNA) was first performed in singleplex using TaqMan 
probes to ensure the extraction process and real-time PCR reactions were not inhibited before 
multiplexing it with C. pneumoniae. No amplicon was detected in any negative controls. All 
amplicons of singleplex reactions were separated in 2% agarose gels stained with ethidium 
bromide (see appendix D) and those from multiplex reactions on 3% agarose gels.  
 
A large amount of non-specific product was produced as evidenced by agarose gel 
electrophoresis (Figures D13-D19). Both internal controls were amplified for all three patient 
samples as seen by real-time PCR results. Tables 3.1 and 3.2 give a summary of the comparison 
between results obtained from Seeplex® Pneumobacter and Seeplex RV5 ACE detection kits 
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(Figure 3.61 and 3.62 respectively) and real-time PCR assays (appendix E). Results obtained are 
in agreement for all three detection methods for L. pneumophila, C. pneumoniae, FluB, hMPV, 
PIV1, PIV3, AdV and RSV. hMPV was excluded as an organism infecting patient 1 in lane 5 
(Figure 3.62) because it was not detected by real-time PCR, leaving human rhinovirus or 
coronavirus as possible infecting organisms.  
 
C. psittaci, P. jirovecii, EBV and CMV cannot be detected by the Seeplex kits thus results were 
based only on real-time PCR. Fluorescence observed for real-time PCR corresponded with 
product bands present on the agarose gels: P. jirovecii was detected in patients 1 and 2; C. 
psittaci in patients 1 and 3; EBV in all 3 patients and CMV only in patient 3.  
 
Table 3.1: Comparison of results obtained from real-time PCR assays and the Seeplex® Pneumobacter ACE 
detection kit. 
 
Target organism Sample source Real-time PCR result Seeplex kit result 
Mycoplasma pneumoniae 
  
  
Patient 1 absent absent 
Patient 2 PRESENT absent 
Patient 3 PRESENT absent 
Legionella pneumophila 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 absent absent 
Chlamydia pneumoniae 
  
  
Patient 1 PRESENT PRESENT 
Patient 2 PRESENT PRESENT 
Patient 3 PRESENT PRESENT 
Pneumocystis jirovecii 
  
  
Patient 1 PRESENT aCND 
Patient 2 PRESENT CND 
Patient 3 absent CND 
Chlamydia psittaci 
  
  
Patient 1 PRESENT CND 
Patient 2 absent CND 
Patient 3 PRESENT CND 
GAPDH (DNA) 
  
  
Patient 1 PRESENT PRESENT 
Patient 2 PRESENT PRESENT 
Patient 3 PRESENT PRESENT 
aCND: organism cannot be detected using the Seeplex kit 
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In some cases such as the detection of PIV2, FluA and M. pneumoniae, results did not correspond 
in both detection methods. Real-time PCR detected PIV2 in patient 2, M. pneumoniae in patients 
2 and 3 and FluA in patient 3 but Seeplex detection kits were not able to identify them. This may 
have been due to the greater sensitivity of the real-time PCR assays (1 copy/µl) compared to the 
Seeplex detection kits (3.3 copies/µl). 
 
Table 3.2: Comparison of results obtained from real-time PCR assays and the Seeplex® RV5 ACE detection kit. 
 
Target organism Sample source Real-time PCR result Seeplex kit result 
Influenza A virus 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 PRESENT absent 
Influenza B virus 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 absent absent 
Human metapneumovirus 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 absent absent 
Parainfluenza virus 1 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 absent absent 
Parainfluenza virus 3 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 absent absent 
Adenovirus 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 absent absent 
Respiratory syncytial virus 
  
  
Patient 1 absent absent 
Patient 2 absent absent 
Patient 3 absent absent 
Cytomegalovirus 
  
  
Patient 1 absent bCND 
Patient 2 absent CND 
Patient 3 PRESENT CND 
Epstein-Barr virus 
  
  
Patient 1 PRESENT CND 
Patient 2 PRESENT CND 
Patient 3 PRESENT CND 
Parainfluenza virus 2 
  
  
Patient 1 absent absent 
Patient 2 PRESENT absent 
Patient 3 absent absent 
GAPDH (RNA) 
  
  
Patient 1 PRESENT PRESENT 
Patient 2 PRESENT PRESENT 
Patient 3 PRESENT PRESENT 
bCND: organism cannot be detected using the Seeplex kit 
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3.10. Pathogen detection using microbiological methods 
Microbiological methods were used to detect organisms present in sputum samples of the 3 CAP 
patients and were performed by the microbiological laboratory at Charlotte Maxeke 
Johannesburg Hospital. Patients 2 and 3 were blood culture negative and their sputum samples 
tested positive for S. pneumoniae and negative for H. influenzae. H. influenzae may not have 
been detected in these patients due to the low quality of sputum collected indicated by the 
negative Bartlett score obtained (-1). Patient 1 tested positive for S. pneumoniae in blood and 
patient 3 for Staphylococcus aureus. 
 
In summary, all three CAP patients investigated in this study had viral and bacterial co-infections 
and these are outlined in table 3.3. In addition, patients 2 and 3 were infected with P. jirovecii. 
The ability of real-time PCR assays used in this study to detect all these organisms demonstrates 
that it could be used for surveillance and prevalence studies. 
 
Table 3.3: Diagnosis of patients 1, 2 and 3. Real-time PCR and Seeplex® Pneumobacter and RV5 ACE detection 
kits were used in parallel to detect organisms infecting these patients. 
 
Subject Infecting organisms 
Patient 1  EBV, M. pneumoniae, C. pneumoniae, P. jirovecii, C. psittaci, S. pneumoniae, H. influenzae, Others 2 (RV or CoV) 
Patient 2  EBV, PIV2, M. pneumoniae, C. pneumoniae, P. jirovecii, S. pneumoniae, H. influenzae 
Patient 3  FluA, CMV, EBV, C. pneumoniae, C. psittaci, S. pneumoniae, S. aureus, H. influenzae 
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CHAPTER 4: DISCUSSION  
 
 
 
A wide range of organisms are responsible for causing community-acquired pneumonia. At 
present, many of these remain unidentified, which may be due to infrequent test requests, the 
lack of sensitivity of the detection methods employed, agents as yet undescribed, presence of 
viral inhibitors, low copy number in the clinical sample, and poor specimen collection and 
handling (Henrickson, 2004). Before implementing a molecular technique for diagnostic or 
surveillance purposes, several issues must be addressed to ascertain that the method is suitable: 
which clinical specimens are to be tested; what are the target organisms; will this technique be 
sensitive and specific enough; is it fast enough, simple enough and is it of clinical relevance.  
 
The first aim of this study was to establish a DNA extraction method for isolation of both DNA 
and RNA from patient sputa and nasopharyngeal swabs that permits downstream PCR analysis. 
Sputum samples and nasopharyngeal swabs were to be obtained from TB negative CAP 
patients. Sputum samples were to be tested for non-viral agents of CAP (M. pneumoniae, C. 
pneumoniae, C. psittaci, P. jirovecii and L. pneumophila) and nasopharyngeal swabs for viral 
agents of CAP (PIV1, 2 and 3, AdV, RSV, FluA and B, CMV, hMPV and EBV).  
 
4.1.NucliSens miniMAG System (miniMag) for nucleic acid extraction 
Three patient samples were collected, which were too few to be representative of CAP locally. 
Therefore, in addition to these patient samples, simulations of 2 nasopharyngeal swabs and 2 
sputum samples was performed to evaluate the test methods. The miniMag was used to extract 
nucleic acid from all samples. The main concern was to effectively extract nucleic acid from the 
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samples and to eliminate polymerase enzyme inhibitors, especially in sputum samples, as they 
have a direct influence on the result of amplification.  
 
The miniMag procedure is based on the use of magnetic particles, consisting mainly of iron 
oxide particles (Fe3O4) (Saiyed et al., 2003) in combination with silica. It represents a universal, 
highly flexible extraction instrument in which (a) different sample input and volumes within the 
same run are possible, (b) up to 12 samples can be processed in parallel, (c) DNA and RNA 
extraction can be performed within the same run and in the same tube, (d) the nucleic acid 
extract can be used for both DNA and cDNA amplification. The silica specifically binds to the 
nucleic acids while contaminating substances or PCR inhibitors that may be present in the 
sample are effectively removed. This makes this method ideal for use with human specimens, 
especially sputum samples, which usually contain a large amount of inhibitors and contaminants 
that may inhibit downstream applications.  
 
Tang and colleagues (Tang et al., 2005) performed a comparative validation on three nucleic 
acid extraction systems on urine specimens. Two of them were manual while the other one was 
the semi-automated miniMag used in this study. They observed that the miniMag produced the 
highest quality of nucleic acids and had the best precision amongst the three extraction systems 
despite it requiring significantly more hands-on time (45 min).  
 
In our study, GAPDH (DNA) and GAPDH (RNA) were amplified by real-time PCR in all 
patient samples suggesting that minimal inhibition was experienced. All organisms used to 
spike the sample simulations were detected by both real-time PCR and Seeplex detection kits. 
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The results suggest that nucleic acid extraction using the miniMag was successful. The miniMag 
was user-friendly and had a hands-on-time of approximately 50 min. 
 
The second aim of the study was to establish molecular methods for the rapid, qualitative 
detection of all the organisms investigated.  
 
4.2.Molecular methods 
4.2.1. Real-time PCR assays 
Six multiplex reactions were successfully developed to simultaneously detect 12 organisms and 
the internal control GAPDH (DNA) using TaqMan probes. These multiplex reactions were 
grouped as follows: (i) Influenza A, Influenza B and hMPV; (ii) PIV1 and PIV3; (iii) EBV and 
CMV; (iv) AdV and RSV; (v) M. pneumoniae and L. pneumophila; and (vi) C. pneumoniae and 
GAPDH (DNA). C. psittaci, P. jirovecii, PIV2 and GAPDH (RNA) were detected in singleplex 
using SYBR Green I as they could not be included into the multiplex reactions and SYBR 
Green I was the more cost-effective option. All the organisms incorporated into the multiplex 
reactions were at first detected in singleplex using SYBR Green I to ensure the primers and 
reaction conditions worked adequately, and then with TaqMan probes individually before being 
multiplexed  
 
4.2.2. Seeplex detection kits 
Two Seeplex detection kits were also evaluated for the detection of respiratory pathogens using 
patient samples and simulations. The Seeplex® Pneumobacter ACE detection kit was used for 
the detection of M. pneumoniae, L. pneumophila, S. pneumoniae, H. influenzae, and C. 
pneumoniae, while the Seeplex® RV5 ACE detection kit was used to detect Influenza A virus, 
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Influenza B virus, human respiratory syncytial virus A or B, Others 1 (human adenovirus, 
human parainfluenza virus 1, 2, and 3, human bocavirus), Others 2 (human metapneumovirus, 
human coronavirus 229E, NL63, OC43 and HKU1, human rhinovirus A and B and an internal 
control. The Seeplex kits successfully detected all organisms used to spike sputum samples and 
nasopharyngeal swabs. Co-infections in all patients were observed. 
 
4.3.Sensitivity of real-time PCR assays using TaqMan probes 
Plasmids containing target DNA were constructed and used in assays to enable detection limit 
analysis. Results obtained showed that the assays were sufficiently sensitive, with the majority 
detecting 1 copy/µl. The CMV and L. pneumophila assays were the only ones with a detection 
limit of 10 copies. Multiplex reactions reflected the same sensitivities as the singleplex 
reactions, indicating that two or more organisms at low concentrations in the same sample could 
be detected in the multiplex assays. This suggests that these assays are sensitive enough to be 
applied in a clinical setting for the detection of CAP and maybe of use diagnostically. 
 
Using plasmids coding for the target sequence has the advantage that once constructed, they can 
be prepared in large amounts and can be stored without significant degradation for long periods 
at -20oC. Long-term storage of transformed E. coli also permits continuity and consistency of 
the positive control DNA for future assays.  
 
4.4.Fluorescence intensity is dependent on the fluorescence dye attached to the probe 
Fluorescence intensity was observed to be higher in the majority of reactions involving probes 
with the FAM, CY5 and CY5.5 dyes compared to those coupled to HEX. FAM is a popular 
choice for use in singleplex reactions as a fluorophore since it has a very strong fluorescence 
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signal. Some researchers believe that this makes FAM unsuitable for multiplexing (Cirino et al., 
2007). However, in our experience, FAM was shown to have strong fluorescence, but did not 
mask the fluorescence emitted by other dyes during multiplexing. Mackay (2007) states that 
fluorescence is generally lower in multiplex reactions than it is in singleplex reactions due to 
limiting primer and probe concentrations when multiplexing. This effect was not observed in 
this study with the majority of multiplex reactions exhibiting higher fluorescence than 
singleplex reactions. This observation may be due to the different master mixes used in 
singleplex and multiplex reactions. The iQTM Multiplex Powermix (Bio-Rad) used for multiplex 
reactions has been optimized to deliver maximum PCR efficiency, sensitivity and precision in 
multiplex reactions as compared to singleplex probe assays. 
 
4.5.TaqMan probes for real-time PCR assays 
When the TaqMan probes were first reconstituted, Ct values observed were lower than those 
generated when using SYBR Green I. After approximately 6 months, fluorescence levels of the 
TaqMan probes were observed to have decreased drastically. The most marked instance was 
FluB which initially had a maximum fluorescence level of 0.55 and 6 months later, had a 
fluorescence of 0.01 even though the same reagents and reaction conditions were used. This is 
believed to be a result of probe degradation over time. Probes were supplied in the lyophilized 
form and reconstituted in Tris-EDTA (TE) buffer. Probe stock solutions were stored at -20oC 
and only thawed once to make up fresh working solution when fluorescence was observed to 
decrease. The probe working solutions were stored in the fridge (4oC) and in the dark (wrapped 
in foil and in a black bag) as recommended by TIB MolBiol. The same batch of probes, 
manufactured at the same time and stored by the manufacturer, was requested from TIB 
MolBiol. These too produced a similarly low level of fluorescence (results not shown). 
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Although TaqMan probes have been reported to have a longer shelf-life at -20oC, and it may 
have been preferable to aliquot the working solution and store it at that temperature, the 
observed decrease in fluorescence using the same batch of probes stored by TIB MolBiol 
suggests that probe degradation occurs primarily due to time related decay. Primer degradation 
was ruled out as a cause of reduced fluorescence levels since they were evaluated with SYBR 
Green I and fluorescence was observed to be high. Probe degradation was furthermore reflected 
in some of the real-time PCR amplification curves (PIV1, PIV3, CMV and hMPV) that did not 
display a typical exponential curve. This is also reported to have been observed in other 
laboratories (personal communication Jasmin Dehnhard, TIB Molbiol). 
 
The process of probe degradation over time is a problem, as evidenced by the lower 
fluorescence of the TaqMan assays. Two degradation scenarios can be envisioned - cleavage of 
the oligonucleotide, or photobleaching of the fluorescent dye. In the former, the fluorophore is 
separated from the quencher resulting in an increase in fluorescence because the fluorophore is 
no longer quenched. This fluorescence is however not evident from the amplification curves 
generated by the Chromo4 since the baseline fluorescence is subtracted automatically in each 
well before increases in fluorescence are measured. In the latter, the fluorophore is bleached 
over time resulting in lower fluorescence. The outcome in both cases would be similar – a 
lowered maximum fluorescence.  
 
Efficiency of PCR amplification can be influenced by several parameters: magnesium and salt 
concentrations, reaction conditions (i.e. time and temperature), PCR target size and 
composition, primer and probe sequences, and sample purity (Heid et al., 1996). In the case of 
real-time PCR, the binding of fluorescent dyes and labelled probes to the DNA results in a 
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signal that is used as a surrogate indicator of PCR efficiency. The low PCR efficiencies 
generated for reactions involving TaqMan probes were unexpected and are not believed to be a 
true reflection of the actual amplification efficiencies. This is qualitatively supported by the 
strong positive signals obtained by standard gel electrophoresis of PCR products in cases where 
low fluorescence and efficiencies were observed. It is unclear what effect the suspected probe 
degradation would have on the efficiency, since the kinetics of probe binding and hydrolysis 
should be unchanged, although the fluorescence intensity observed would be lower.  
 
4.6.Multiplex real-time PCR reactions 
Although the majority of primers and probes used in 4 out of 6 multiplex reactions were adopted 
from literature, the format in which the organisms were grouped to be multiplexed in 3 out of 
the 4 reactions was novel. The primer and probe sequences of the multiplex groups (i) M. 
pneumoniae and L. pneumophila, and (ii) C. pneumoniae and GAPDH (DNA), were designed in 
this study using the Beacon Designer software program (Biosoft International). The multiplex 
reactions of (i) FluA, FluB and hMPV, (ii) PIV1 and PIV3 and (iii) AdV and RSV were 
performed using primers and probes adopted from literature, but grouped in a different manner 
from the publications from which they were taken. Even with these multiplex reactions not 
being performed as per the original publication, the desired amplicons were still produced and 
the multiplex reactions were sensitive. Up to 3 probe and primer combinations per organism 
were evaluated for the following multiplex groups: FluA, FluB and hMPV and PIV1 and PIV3, 
and 2 combinations for L. pneumophila and M. pneumoniae and C. pneumoniae and GAPDH 
(DNA) before a grouping that functioned well and could be multiplexed was obtained. The most 
complex multiplex combination was the FluA, FluB and hMPV multiplex reaction, which 
despite having a range of primers, probes and targets in the same reaction tube, still successfully 
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amplified all 3 targets at a detection limit of 1 copy/µl. Regardless of the decrease in 
fluorescence that was observed over time in the TaqMan based reactions, our assays proved to 
be capable of detecting diverse organisms without a dramatic reduction in sensitivity. 
 
4.7.Bacterial and viral detection on patient samples and simulations 
Since kit based methods for the CAP study were found to be prohibitively expensive, in-house 
real-time PCR assays were developed. The more reasonably priced conventional PCR kits from 
Seegene were only launched in the second-half of 2008. 
 
For the detection of respiratory agents infecting patients 1, 2 and 3, real-time PCR was used in 
parallel with the Seeplex® Pneumobacter ACE detection kit and the Seeplex® RV5 ACE 
detection kit. These detection methods were also used to confirm the presence of organisms 
used to spike the simulated patient samples as well as to identify any other organisms that may 
have been present. The reagent cost for singleplex real-time PCR is R197.14 whilst multiplex 
reactions cost approximately R95.61 per organism per reaction for both 2 target and 3 target 
specific reactions. Multiplex reactions are cheaper, have reduced handling time and occupy less 
space in the thermocycler as compared to singleplex reactions, and therefore were the option of 
choice. Seeplex® Pneumobacter (6 organisms) and the Seeplex® RV5 (3 organisms and 
“Others 1” and “Others 2”) ACE detection kits cost R170 and R240 respectively per reaction. 
More organisms can be detected per reaction by the kits than by real-time PCR; however, 
comparison of overall affordability of the two detection methods depends on the organisms one 
is interested in. Seeplex® RV/PB18 auto-sequencer electrophoresis (ASE) detection kit which 
covers a larger panel of respiratory pathogens (Influenza A virus, Influenza B virus, human 
respiratory syncytial virus A and B, human parainfluenza virus 1, 2, and 3, human bocavirus, 
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human adenovirus, human coronavirus OC43/HKU1, human coronavirus 229E/NL63, human 
rhinovirus, human enterovirus, M. pneumoniae, L. pneumophila, S. pneumoniae, H. influenzae 
and C. pneumoniae) could have also been used instead of the Seeplex® Pneumobacter and the 
Seeplex® RV5 ACE detection kits, but due to the cost (R481 per reaction) and the requirement 
of a genetic analyzer for product detection, this kit was not selected.  
 
Although Seeplex detection kits are marginally less sensitive compared to real-time PCR, 
reactions involving these kits are easier to perform and do not require complex equipment. 
Consequently, the Seeplex® Pneumobacter ACE detection kit and the Seeplex® RV5 ACE 
detection kit were used to complement real-time PCR. 
 
Results obtained in this study indicate minimal non-specific amplification when using Seeplex 
detection kits. Multiplex real-time PCR reactions on the contrary amplified non-specific 
products in clinical samples as evidenced by agarose gel electrophoresis. This indicates that due 
to the presence of a range of organisms and other substances in the patient samples and failure 
to further optimize real-time PCR reactions used due to time limitations, these reactions were 
not as specific as they were hoped to be. The Seeplex ACE detection kits were validated and 
tested for cross reactivity and sensitivity by the manufacturer and are reported to have a low rate 
of false positives. Seeplex kits were reported to have a sensitivity of 10 copies/3µl while the 
real-time PCR singleplex and multiplex assays of our study were mostly found to have a 
sensitivity of 1 copy/µl.  
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Real-time PCR assays detected FluA in the nasopharyngeal swabs of patient 3, M. pneumoniae 
in the sputum samples of patients 2 and 3 and PIV2 in the nasopharyngeal swab of patient 2. 
Seeplex kits failed to detect these organisms suggesting that they were present in concentrations 
below the detection limit of the kits. Viral pneumonias caused by influenza viruses can be life 
threatening in adults and immunocompromised patients due to direct involvement of lung tissue 
or by secondary bacterial infections due to S. pneumoniae, S. aureus, H. influenzae and other 
gram-negative organisms as is the case in patient 3 who is co-infected by all these organisms 
(Oosterheert et al., 2003). 
 
The multiplex real-time PCR reaction of CMV and EBV detected co-infection with both these 
organisms in patient 3. This indicates that multiplex real-time PCR can detect all organisms 
targeted, even in clinical samples. 
 
The Seeplex® Pneumobacter ACE detection kit detected H. influenzae in all patient sputum 
samples and simulations. Murphy (2003) states that non-typeable (non-encapsulated) H. 
influenzae is a common cause of pneumonia and lower respiratory tract infections in adults. It is 
also the most frequent cause of infections in patients with cystic fibrosis hence the detection of 
this bacterium in simulated sputum samples used in this study.  
 
Results obtained in this study support evidence obtained by Lee et al., (2002) that atypical 
pathogens cause CAP more frequently than was previously thought. Marston et al., (1997) 
(Marston et al., 1997) showed that atypical pathogens cause up to 60% of etiology-proven CAP 
cases. 
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4.8.Limitations of study 
This study has several limitations. Firstly, the low number of patient samples prevented 
adequate validation of our real-time assays as well as the Seeplex detection kits. The initial aim 
of the study was to enroll 100 patients presenting with CAP symptoms from whom sputa and 
nasopharyngeal swabs would be obtained. However, due to factors beyond our control, only 3 
patients were enrolled. Secondly, although real-time PCR produced rapid results and amplicons 
could be detected based on real-time PCR alone, in some cases fluorescence and efficiency were 
low. It therefore became necessary to analyze the amplicons by gel electrophoresis to confirm 
results. Also, due to the limited number of organisms that could be detected by both real-time 
PCR and the Seeplex detection kits, it could not be confirmed whether the other organism 
infecting patient 1 was RV or CoV, therefore stressing the need to implement additional means 
to detect a wider range of organisms. Thirdly, due to complications experienced with probe 
design, C. psittaci and PIV2 could not be incorporated into any multiplex real-time PCR 
combination. Lastly, time was a limiting factor in this study and as a result, real-time PCR 
assays could not be fully optimized to reduce the formation of primer-dimer artifacts and non-
specific amplification.  
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CHAPTER 5: CONCLUSION 
 
 
 
More often than not, empiric treatment of CAP is based upon available epidemiological data 
and clinical experience. It is therefore important to have data on which pathogens are prevalent 
locally. Such a prevalence study requires the establishment of detection methods to efficiently 
identify the most common causative agents of CAP.  
 
The goal of this study was to establish a nucleic acid extraction method for isolation of both 
DNA and RNA from patient sputa and nasopharyngeal swabs and thereafter, to establish 
molecular methods for the rapid, qualitative detection of all the organisms investigated.  
 
We have successfully used the miniMag to extract nucleic acids from patient samples and 
simulated samples. Multiplex and singleplex real-time PCR assays with high sensitivity were 
successfully established for all organisms to detect 15 CAP-associated agents. Six of these 
assays were performed in multiplex to simultaneously detect 12 organisms and a GAPDH 
(DNA) internal control, and 4 were performed in singleplex. In this pilot study, the assays were 
performed on simulated samples as well as 3 patient samples in parallel with Seeplex 
commercial PCR kits. The results obtained were promising in terms of establishing reliable, 
rapid methods of organism detection for potential causative agents of CAP. 
 
On early reception of the patient sample, analysis using the Seeplex® Pneumobacter detection 
kit can be completed within the same day to detect 6 organisms and one and a half days when 
using the Seeplex® RV5 detection kit to detect 3 organisms and confirm the identity of 
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organisms in the “Others” group using real-time PCR. When using the real-time PCR assays, 
with a single real-time PCR cycler, analysis of 15 organisms can be completed within 2 days. It 
would be advisable to use these methods to complement each other since some respiratory 
pathogens such as hRV, BoV, CoV, H. influenzae, S. pneumoniae and B. pertussis that are 
included in the detection panel of the Seeplex kits were not included in the design of the real-
time PCR assays whilst organisms such as CMV, EBV, C. psittaci and P. jirovecii, which are 
detected by the real-time PCR assays in this study cannot be detected by the kits and require 
further testing. The real-time PCR assays could therefore be used as a follow-on system to 
identify organisms that the Seeplex® RV5 ACE detection kit cannot differentiate between, 
namely, Others 1 (AdV, PIV1, 2, 3 or BoV) and Others 2 (hMPV, hRV or CoV). However, 
using real-time PCR with TaqMan probes for the diagnosis of CAP would mean purchasing 
fresh probes every 6 months due to reduction in fluorescence and PCR efficiency, making the 
real-time option best for periodic surveillance and prevalence purposes which can be completed 
in less than 6 months. Using this detection option for diagnostic purposes would require a 
redesign of probes, such as the use of Molecular Beacon aptamers which have a longer shelf-life 
(Drake and Tan et al., 2004) and increased hybridisation specificity as a result, reduce non-
specific amplification. 
 
Preliminary comparison of Seeplex kits and real-time PCR suggests that the two can be used to 
complement each other for prevalence studies and potentially for selected diagnostic 
applications. 
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CHAPTER 7: APPENDIX A 
 
 
 
7.1.Buffers, Media and Stains 
 
1. 2% Agarose (30ml) 
 0.6g Agarose    
30ml 1x TAE buffer 
1.5µl Ethidium bromide (10µg/ml) 
 
2. 3% Agarose (30ml) 
 0.9g Agarose 
 30ml 1x TAE buffer 
 1.5µl Ethidium bromide (10µg/ml) 
 
3. 30% sterile glycerol (100ml) 
 30ml glycerol (neat) 
d.H2O 
Make up to 100ml with dH2O and autoclave. 
 
Buffers 
 
Otherwise stated, all buffers were autoclaved. 
 
1. TE Buffer 
10mM Tris-HCl, pH 8.0 
1mM EDTA  
d.H2O 
 
2. 1M Tris-HCl pH 8.3 (200ml) 
24.2g Tris base 
d.H2O 
Dissolve powder in 150ml d.H2O. Add approximately 8.4 ml concentrated HCl for a solution 
with a pH of 8.3, and check with a pH meter. 
 
3. Protenaise K buffer (250µl) 
 12.5µl 20mg/ml proteinase k 
 12.5µl 10% SDS 
 5µl 1M Tris-HCl (pH 8.3) 
Make up to 250µl with water. Buffer was not autoclaved 
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4. 10% SDS (100ml) 
10g SDS 
d.H2O 
Add SDS powder to d.H2O, and make up to 100mL. Heat at 68°C to dissolve the powder. Adjust 
pH to 7.2 with 1M HCl. Buffer was not autoclaved. 
 
5. 50x TAE buffer (100ml)  
24.2g Tris base 
5.7ml glacial acetic acid 
10ml 0.5M EDTA (pH 8) 
d.H2O 
Dissolve Tris and EDTA.2H2O in d.H2O. Add the acetic acid and make up to 100ml with d.H2O. 
 
6. 0.5M EDTA (1L) 
186.1g Na2EDTA.2H2O 
d.H2O 
Dissolve the Na2EDTA.2H2O powder in d.H2O, and adjust pH to 8.0 with 10M NaOH (~50mL). 
Make up to 1L with d.H2O. 
 
7. 1M HCl (1L) 
 86.2mL concentrated HCl 
d.H2O 
Add 86.2ml concentrated HCl to 913.8ml d.H2O. Buffer was not autoclave. 
 
Media 
 
1. Luria Bertani broth 
5.0g Tryptone 
10.0g Yeast extract 
5.0g Sodium chloride 
 Dissolve in 1L d.H2O. 
 
Stains 
 
1. Ethidium Bromide (10mg/ml) (10ml) 
100mg Ethidium bromide 
d.H2O 
Make up to 10ml with d.H2O. Do not autoclave. Store in the dark 
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CHAPTER 7: APPENDIX B 
 
 
 
7.2.Agarose gels of singleplex real-time PCR reactions: positive controls and sensitivity assays 
 
     
 
 



Figure B1: Agarose gel electrophoresis of CMV  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 
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

Figure B2: Agarose gel electrophoresis of EBV  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 
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Figure B3: Agarose gel electrophoresis of PIV1  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 
 

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Figure B4: Agarose gel electrophoresis of AdV  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 



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
Figure B5: Agarose gel electrophoresis of PIV3  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 
 

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Figure B6: Agarose gel electrophoresis of RSV  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 


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Figure B7: Agarose gel electrophoresis of hMPV  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 
 
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Figure B8: Agarose gel electrophoresis of (A) Positive 
controls of FluA and FluB using SYBR Green I;  
(B) Positive control of FluB using TaqMan probes; 
(C) Positive control of FluA using TaqMan probes;  
(D) Sensitivity assay of FluA performed on plasmids using 
TaqMan probes; and (E) Sensitivity assay of FluB 
performed on plasmids using TaqMan probes. 
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Figure B9: Agarose gel electrophoresis of (A) Positive 
controls of M. pneumoniae and L. pneumophila using 
SYBR Green I; (B) Positive control of M. pneumoniae 
using TaqMan probes; (C) Positive control of L. 
pneumophila using TaqMan probes; (D) Sensitivity assay 
of L. pneumophila performed on plasmids using TaqMan 
probes; and (E) Sensitivity assay of M. pneumoniae 
performed on plasmids using TaqMan probes. 
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
Figure B10: Agarose gel electrophoresis of (A) Positive control of GAPDH (DNA) using SYBR Green I; (B) Positive 
control of GAPDH (RNA) using SYBR Green I; (C) Positive control of GAPDH (DNA) using TaqMan probes; and (D) 
Sensitivity assay of GAPDH (DNA) performed on plasmids using TaqMan probes. 

 

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
Figure B11: Agarose gel electrophoresis of C. pneumoniae  
(A) Positive control using SYBR Green I; (B) Positive 
control using TaqMan probes; and (C) Sensitivity assay 
performed on plasmids using TaqMan probes. 
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Figure B12: Agarose gel electrophoresis of P. jirovecii (A) Positive control using SYBR Green I; (B) Sensitivity assay 
performed on plasmids using SYBR Green I. 
      
 
Figure B13: Agarose gel electrophoresis of C. psittaci (A) Positive control using SYBR Green I; (B) Sensitivity assay 
performed on plasmids using SYBR Green I. 
 

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Figure B14: Agarose gel electrophoresis of PIV2 (A) Positive control using SYBR Green I; (B) Sensitivity assay performed on 
plasmids using SYBR Green I. 
 
 
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CHAPTER 7: APPENDIX C 
 
 
 
7.3.Agarose gels of multiplex real-time PCR reactions: positive controls and sensitivity assays 
 
      
 
Figure C1: Agarose gel of CMV and EBV multiplex reaction obtained using TaqMan probes on (A) Positive controls;  
(B) Plasmids at the lowest detectable concentration. 
      
 
Figure C2: Agarose gel of AdV and RSV multiplex reaction obtained using TaqMan probes on (A) Positive controls;  
(B) Plasmids at the lowest detectable concentration. 


 
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Figure C3: Agarose gel of FluA, FluB and hMPV multiplex reaction obtained using TaqMan probes on (A) Positive controls;  
(B) Plasmids at the lowest detectable concentration. 
 
      
 
Figure C4: Agarose gel of PIV1 and PIV3 multiplex reaction obtained using TaqMan probes on (A) Positive controls;  
(B) Plasmids at the lowest detectable concentration. 
 
 
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Figure C5: Agarose gel of L. pneumophila and M. pneumoniae multiplex reaction obtained using TaqMan probes on  
(A) Positive controls; (B) Plasmids at the lowest detectable concentration. 
 
     
 
Figure C6: Agarose gel of C. pneumoniae and GAPDH (DNA) multiplex reaction obtained using TaqMan probes on (A) 
Positive controls; (B) Plasmids at the lowest detectable concentration. 
 
 
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  CHAPTER 7: APPENDIX D 
 
7.4.Agarose gels of real-time PCR reactions performed on patient samples and simulations  
 
      
 
 
 
 
      
 
Figure D1: Agarose gel of C. pneumoniae real-time PCR 
product obtained from simulated sputum samples. 
Figure D2: Agarose gel of C. psittaci real-time PCR 
product obtained from simulated sputum samples. 
Figure D3: Agarose gel of CMV real-time PCR product 
obtained from simulated nasopharyngeal swabs. 
Figure D4: Agarose gel of FluA real-time PCR 
product obtained from simulated nasopharyngeal swabs. 
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Figure D5: Agarose gel of GAPDH (DNA) real-time PCR 
product obtained from simulated sputum samples. 
Figure D6: Agarose gel of L. pneumophila real-time PCR 
product obtained from simulated sputum samples. 
Figure D7: Agarose gel of C. pneumoniae and GAPDH 
(DNA) multiplex reaction obtained from simulated sputum 
samples.  
Figure D8: Agarose gel of PIV1 real-time PCR product 
obtained from simulated nasopharyngeal swabs. 
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Figure D9: Agarose gel of PIV2 real-time PCR product 
obtained from simulated nasopharyngeal swabs. 
 
Figure D10: Agarose gel of RSV real-time PCR product 
obtained from simulated nasopharyngeal swabs. 
 
Figure D11: Agarose gel of C. psittaci real-time PCR 
product obtained from CAP patient sputum samples. 
Figure D12: Agarose gel of P. jirovecii real-time PCR 
product obtained from CAP patient sputum samples. 
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Figure D13: Agarose gel of PIV2 real-time PCR product 
obtained from CAP patient nasopharyngeal swabs. 
Figure D14: Agarose gel of AdV and RSV multiplex real-
time PCR product obtained from CAP patient 
nasopharyngeal swabs. 
Figure D15: Agarose gel of FluA, FluB and hMPV 
multiplex real-time PCR product obtained from CAP 
patient nasopharyngeal swabs. 
Figure D16: Agarose gel of PIV1 and PIV3 multiplex real-
time PCR product obtained from CAP patient 
nasopharyngeal swabs. 
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Figure D17: Agarose gel of C. pneumoniae and GAPDH 
(DNA) multiplex real-time PCR product obtained from 
CAP patient sputum samples. 
Figure D18: Agarose gel of CMV and EBV multiplex real-
time PCR product obtained from CAP patient 
nasopharyngeal swabs. 
Figure D19: Agarose gel of M. pneumoniae and L. 
pneumophila multiplex real-time PCR product obtained 
from CAP patient sputum samples. 
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CHAPTER 7: APPENDIX E 
 
 
 
7.5.Real-time PCR results for patient samples and simulations 
7.5.1. Pathogen detection in simulated samples 
7.5.1.1.Singleplex reactions 
 
a. GAPDH (DNA) 

 
 
Figure E1: Fluorescence graph of GAPDH (DNA) singleplex reaction performed on nucleic acids extracted from 
spiked sputum samples. Real-time PCR was carried out in duplicate using TaqMan probes. Shown is a plot of 
change in fluorescence signal versus cycle number. 
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b. Influenza A virus  

 
 
Figure E2: Fluorescence graph of FluA singleplex reaction performed on nucleic acids extracted from spiked 
nasopharyngeal swabs. Real-time PCR was carried out in duplicate using TaqMan probes. Shown is a plot of 
change in fluorescence signal versus cycle number. 
 
c. Parainfluenza virus 1  

 
 
Figure E3: Fluorescence graph of PIV1 singleplex reaction performed on nucleic acids extracted from spiked 
nasopharyngeal swabs. Real-time PCR was carried out in duplicate using TaqMan probes. Shown is a plot of 
change in fluorescence signal versus cycle number. 
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d. Respiratory syncytial virus  
 
 
 
Figure E4: Fluorescence graph of RSV singleplex reaction performed on nucleic acids extracted from spiked 
nasopharyngeal swabs. Real-time PCR was carried out in duplicate using TaqMan probes. Shown is a plot of 
change in fluorescence signal versus cycle number. 
 
Cytomegalovirus  
  
 
 
Figure E5: Fluorescence graph of CMV singleplex reaction performed on nucleic acids extracted from spiked 
nasopharyngeal swabs. Real-time PCR was carried out in duplicate using TaqMan probes. Shown is a plot of 
change in fluorescence signal versus cycle number. 
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e. L. pneumophila  
   
  
 
Figure E6: Fluorescence graph of L. pneumophila singleplex reaction performed on nucleic acids extracted from 
spiked sputum samples. Real-time PCR was carried out in duplicate using TaqMan probes. Shown is a plot of 
change in fluorescence signal versus cycle number. 
 
C. pneumoniae  
  
 
 
Figure E7: Fluorescence graph of C. pneumoniae singleplex reaction performed on nucleic acids extracted from 
spiked sputum samples. Real-time PCR was carried out in duplicate using TaqMan probes. Shown is a plot of 
change in fluorescence signal versus cycle number. 
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f. C. psittaci 
" '(!  
 
 
Figure E8: Melting curve analysis of C. psittaci singleplex reaction performed on nucleic acids extracted from 
spiked sputum samples. Real-time PCR was carried out in duplicate using SYBR Green I. The signature melting 
temperature of C. psittaci (81oC) is indicated by the sharp red and green peaks. Shown is a plot of temperature 
versus fluorescence signal. 
 
g. Parainfluenza virus 2 
" '(!  
  
 
Figure E9: Melting curve analysis of PIV2 singleplex reaction performed on nucleic acids extracted from spiked 
nasopharyngeal swabs. Real-time PCR was carried out in duplicate using SYBR Green I. The signature melting 
temperature of PIV2 (78oC) is indicated by the sharp red and green peaks. Shown is a plot of temperature versus 
fluorescence signal. 
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7.5.1.2.Multiplex reactions 
a. GAPDH (DNA) and C. pneumoniae  
 

 
 
Figure E10a: Fluorescence graph of GAPDH (DNA) multiplex reaction performed on nucleic acids extracted from 
spiked sputum samples. Real-time PCR was performed in duplicate. Shown is a plot of change in fluorescence 
signal versus cycle number obtained using TaqMan probes. 
 
  
  
 
Figure E10b: Fluorescence graph of C. pneumoniae multiplex reaction performed on nucleic acids extracted from 
spiked sputum samples. Real-time PCR was performed in duplicate. Shown is a plot of change in fluorescence 
signal versus cycle number obtained using TaqMan probes. 
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7.5.2. Pathogen detection in CAP patient samples 
7.5.2.1.Singleplex reactions 
a. GAPDH (DNA): Patient sputum samples 
 

  
 
Figure E11: Fluorescence graph of GAPDH (DNA) singleplex reaction performed on nucleic acids extracted from 
sputum samples taken from CAP patients. Real-time PCR was performed in duplicate using TaqMan probes. 
Shown is a plot of change in fluorescence signal versus cycle number. 
 
b. GAPDH (DNA): Patient nasopharyngeal swabs 
 

  
 
Figure E12: Fluorescence graph of GAPDH (DNA) singleplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Real-time PCR was performed in duplicate using TaqMan probes. 
Shown is a plot of change in fluorescence signal versus cycle number. 
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GAPDH (RNA): Patient nasopharyngeal swabs 
 
 " '(!  
  
 
Figure E13: Melting curve analysis of GAPDH (RNA) singleplex reaction performed on nucleic acids extracted 
from sputum samples taken from CAP patients. Real-time PCR was performed in duplicate using SYBR Green I. 
Shown is a plot of temperature versus fluorescence signal. 
 
c. P. jirovecii 
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Figure E14: Melting curve analysis of P. jirovecii singleplex reaction performed on nucleic acids extracted from 
sputum samples taken from CAP patients. Real-time PCR was performed in duplicate using SYBR Green I. Shown 
is a plot of temperature versus fluorescence signal. 
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d. C. psittaci 
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Figure E15: Melting curve analysis of C. psittaci singleplex reaction performed on nucleic acids extracted from 
sputum samples taken from CAP patients. Real-time PCR was performed in duplicate using SYBR Green I. Shown 
is a plot of temperature versus fluorescence signal. 
 
e. PIV2 
 
 " '(!  
  
 
Figure E16: Melting curve analysis of PIV2 singleplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Real-time PCR was performed in duplicate using SYBR Green I. 
Shown is a plot of temperature versus fluorescence signal. 
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7.5.2.2.Multiplex reactions 
 
a. PIV1 and PIV3 
 
 
  
 
Figure E17a: Fluorescence graph of PIV1 multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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Figure E17b: Fluorescence graph of PIV3 multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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b. CMV and EBV 
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Figure E18a: Fluorescence graph of CMV multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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Figure E18b: Fluorescence graph of EBV multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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c. M. pneumoniae and L. pneumophila 
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Figure E19a: Fluorescence graph of M. pneumoniae multiplex reaction performed on nucleic acids extracted from 
sputum samples taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle number 
obtained using TaqMan probes. 
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Figure E19b: Fluorescence graph of L. pneumophila multiplex reaction performed on nucleic acids extracted from 
sputum samples taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle number 
obtained using TaqMan probes. 
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d. RSV and AdV 
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Figure E20a: Fluorescence graph of RSV multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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Figure E20b: Fluorescence graph of AdV multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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e. C. pneumoniae and GAPDH (DNA) 
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Figure E21a: Fluorescence graph of GAPDH (DNA) multiplex reaction performed on nucleic acids extracted from 
sputum samples taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle number 
obtained using TaqMan probes. 
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Figure E21b: Fluorescence graph of C. pneumoniae multiplex reaction performed on nucleic acids extracted from 
sputum samples taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle number 
obtained using TaqMan probes. 
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f. FluA, FluB and hMPV 
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Figure E22a: Fluorescence graph of FluA multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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Figure E22b: Fluorescence graph of FluB multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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Figure E22c: Fluorescence graph of hMPV multiplex reaction performed on nucleic acids extracted from 
nasopharyngeal swabs taken from CAP patients. Shown is a plot of change in fluorescence signal versus cycle 
number obtained using TaqMan probes. 
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